var title_f9_5_9296="Retained TT";
var content_f9_5_9296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retained tympanostomy tube with surrounding moist squamous debris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9296=[""].join("\n");
var outline_f9_5_9296=null;
var title_f9_5_9297="4th nerve anatomy";
var content_f9_5_9297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Origin and distribution of the trochlear nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic schematic showing the course of the fourth cranial nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snell RS. Clinical Anatomy, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9297=[""].join("\n");
var outline_f9_5_9297=null;
var title_f9_5_9298="Patient information: Colon polyps (The Basics)";
var content_f9_5_9298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15726\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42063\">",
"           Removing a colon polyp",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7541\">",
"         Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colon polyps (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colon-polyps-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1472297206\">",
"      <span class=\"h1\">",
"       What are colon polyps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colon polyps are tiny growths that form on the inside of the large intestine (also known as the colon) (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). Polyps are very common. Roughly one-third to one-half of all adults have them. They do not usually cause symptoms. But some polyps can be or become cancer, so doctors sometimes remove them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297213\">",
"      <span class=\"h1\">",
"       What are the symptoms of colon polyps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colon polyps do not usually cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297220\">",
"      <span class=\"h1\">",
"       How do doctors find colon polyps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors usually find colon polyps when they are doing screening tests to check for colon or rectal cancer. Cancer screening tests are tests that are done to try and find cancer early, before a person has symptoms. The screening tests for colon and rectal cancer include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Colonoscopy &ndash; Before having a colonoscopy, you will get medicine to help you relax. Then a doctor will put a thin tube into your anus and advance it into your colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). The tube has a camera attached to it, so the doctor can look inside your colon. The tube also has tools on the end, so the doctor can remove pieces of tissue, including polyps. After polyps are removed, they usually go to a lab to be tested for cancer and other problems.",
"       </li>",
"       <li>",
"        Sigmoidoscopy &ndash; A sigmoidoscopy is very similar to a colonoscopy. The only difference is that this test looks only at the first part of the colon, and a colonoscopy looks at the whole colon.",
"       </li>",
"       <li>",
"        CT colonography (also known as virtual colonoscopy) &ndash; For a virtual colonoscopy, you have a special kind of X-ray taken, called a &ldquo;CT scan.&rdquo; This test creates pictures of the colon.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"         Barium",
"        </a>",
"        enema &ndash; During a barium enema, a doctor or nurse squirts a fluid that shows up on X-rays into your rectum. Then he or she takes X-rays to create pictures of the colon.",
"       </li>",
"       <li>",
"        Stool test &ndash; &ldquo;Stool&rdquo; is another word for &ldquo;bowel movements.&rdquo; Stool tests check for blood or abnormal genes in samples of stool. If a stool test indicates that something might be wrong with the colon, doctors usually follow up with a colonoscopy. Then doctors find polyps, if they are there.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297227\">",
"      <span class=\"h1\">",
"       How are colon polyps treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors remove polyps using the same tools they use for a colonoscopy. They can remove polyps either by snipping them off with a special cutting tool, or by catching the polyps in a noose (",
"      <a class=\"graphic graphic_figure graphicRef63967 \" href=\"UTD.htm?41/4/42063\">",
"       figure 3",
"      </a>",
"      )",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297234\">",
"      <span class=\"h1\">",
"       What happens after I have polyps removed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You may need to have a colonoscopy every few years to check for more polyps. In some people polyps come back. And if you had the kind of polyps that could become cancer, your doctor will want to remove them as they appear. Also, if the polyps you had removed were the kind that could become cancer, people in your family might need to be checked for polyps and colon cancer, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297241\">",
"      <span class=\"h1\">",
"       Can colon polyps be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce your chances of getting (more) polyps or colon cancer:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat a diet that is low in fat and high in fruits, vegetables, and fiber",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight",
"       </li>",
"       <li>",
"        Do not smoke",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472297248\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/5/9298?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15726 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9298=[""].join("\n");
var outline_f9_5_9298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297206\">",
"      What are colon polyps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297213\">",
"      What are the symptoms of colon polyps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297220\">",
"      How do doctors find colon polyps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297227\">",
"      How are colon polyps treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297234\">",
"      What happens after I have polyps removed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297241\">",
"      Can colon polyps be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472297248\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42063\">",
"        Removing a colon polyp",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9299="Patient information: Diarrhea in adults (The Basics)";
var content_f9_5_9299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15384\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/557\">",
"          Tips for safe food handling",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/42/2723\">",
"         Patient information: Campylobacter infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/36/25154\">",
"         Patient information: Microscopic colitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/14/7395\">",
"         Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diarrhea in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diarrhea-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H461426764\">",
"      <span class=\"h1\">",
"       What is diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diarrhea describes bowel movements that are runny or watery, and happen 3 or more times in a day. Diarrhea is very common. Most adults have diarrhea about 4 times a year. Just about everyone has it at some point.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426771\">",
"      <span class=\"h1\">",
"       What causes diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diarrhea can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Viruses",
"       </li>",
"       <li>",
"        Bacteria that live in food or water",
"       </li>",
"       <li>",
"        Parasites, such as tiny worms that you can catch in some countries",
"       </li>",
"       <li>",
"        Side effects from some medicines",
"       </li>",
"       <li>",
"        Problems digesting certain types of food",
"       </li>",
"       <li>",
"        Diseases that harm the digestive system (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426778\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Here are some things you can try at home:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink a lot of liquids that have water, salt, and sugar. Good choices are water mixed with juice, flavored soda, and soup broth. If you are drinking enough fluids, your urine will be light yellow or almost clear.",
"       </li>",
"       <li>",
"        Try to eat a little food. Good choices are potatoes, noodles, rice, oatmeal, crackers, bananas, soup, and boiled vegetables. Salty foods help the most.",
"       </li>",
"       <li>",
"        Take a medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"         loperamide",
"        </a>",
"        (sold as Imodium&reg;). It is safe if you do not have a fever or bloody bowel movements.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426785\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Your symptoms still aren&rsquo;t better after 48 hours",
"       </li>",
"       <li>",
"        You have had more than 6 runny bowel movements in 24 hours",
"       </li>",
"       <li>",
"        You have lots of small bowel movements with blood or mucus",
"       </li>",
"       <li>",
"        Your diarrhea is black or bloody",
"       </li>",
"       <li>",
"        You have a fever higher than 101.3&ordm;F (38.5&ordm;C)",
"       </li>",
"       <li>",
"        You have severe belly pain",
"       </li>",
"       <li>",
"        You are 70 or older",
"       </li>",
"       <li>",
"        You have diarrhea after finishing antibiotics",
"       </li>",
"       <li>",
"        Your body has lost too much water. This is called dehydration. Signs include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Lots of diarrhea that is very watery",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Thirst",
"       </li>",
"       <li>",
"        Dry mouth or tongue",
"       </li>",
"       <li>",
"        Muscle cramps",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Urine that is very yellow, or not needing to urinate for more than 5 hours",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426792\">",
"      <span class=\"h1\">",
"       Do I need to have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people don&rsquo;t need any tests at all. But it&rsquo;s possible your doctor will want to do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Tests on a sample of your bowel movements",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These tests can show whether you have an infection, and if so, what kind. They can also show if you are dehydrated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426799\">",
"      <span class=\"h1\">",
"       How is diarrhea treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your diarrhea. You may not need any treatment. If you do, your doctor might recommend:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Antibiotics &ndash; These medicines fight infections.",
"       </li>",
"       <li>",
"        Medicines that ease diarrhea, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"         loperamide",
"        </a>",
"        (sold as Imodium&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11892?source=see_link\">",
"         diphenoxylate",
"        </a>",
"        (sold as Lomotil&reg;), or bismuth&nbsp;subsalicylate (sold as Pepto-Bismol&reg; or Kaopectate&reg;)",
"       </li>",
"       <li>",
"        Fluids through an IV. This is a thin tube that goes into your vein. An IV can help if you have severe dehydration.",
"       </li>",
"       <li>",
"        Stopping some of your medicines",
"       </li>",
"       <li>",
"        Changing the foods you eat",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426806\">",
"      <span class=\"h1\">",
"       Can diarrhea be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting and spreading diarrhea by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Washing your hands after changing diapers, cooking, eating, going to the bathroom, taking out the trash, touching animals, and blowing your nose.",
"       </li>",
"       <li>",
"        Staying home from work or school until you feel better.",
"       </li>",
"       <li>",
"        Paying attention to food safety. Tips include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Not drinking unpasteurized milk or foods made with it",
"       </li>",
"       <li>",
"        Washing fruits and vegetables well before eating them",
"       </li>",
"       <li>",
"        Keeping the refrigerator colder than at 40&ordm;F and the freezer below 0&ordm;F",
"       </li>",
"       <li>",
"        Cooking meat and seafood until well done",
"       </li>",
"       <li>",
"        Cooking eggs until the yolk is firm",
"       </li>",
"       <li>",
"        Washing hands, knives, and cutting boards after they touch raw food",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For more tips on food safety, see the table (",
"      <a class=\"graphic graphic_table graphicRef60529 \" href=\"UTD.htm?0/34/557\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461426813\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/36/25154?source=see_link\">",
"       Patient information: Microscopic colitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"       Patient information: Campylobacter infection (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"       Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/5/9299?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15384 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-78FC411DA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9299=[""].join("\n");
var outline_f9_5_9299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426764\">",
"      What is diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426771\">",
"      What causes diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426778\">",
"      Is there anything I can do on my own to get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426785\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426792\">",
"      Do I need to have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426799\">",
"      How is diarrhea treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426806\">",
"      Can diarrhea be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461426813\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/557\">",
"       Tips for safe food handling",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=related_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=related_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/36/25154?source=related_link\">",
"      Patient information: Microscopic colitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9300="Paraaortic node dissection4";
var content_f9_5_9300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Beginning left paraaortic node dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9300=[""].join("\n");
var outline_f9_5_9300=null;
var title_f9_5_9301="LV wall motion analysis";
var content_f9_5_9301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55855%7ECARD%2F62482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55855%7ECARD%2F62482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Analysis of wall motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 16-segment model for the analysis of left ventricular wall motion, recommended by the American Society of Echocardiography, is shown.",
"    <div class=\"footnotes\">",
"     A: anterior; AL: anterolateral; IL: inferolateral; I: inferior; IS: inferior septum; AS: anterior septum; PL: posterior lateral.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the American Society of Echocardiography.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship of two dimensional views and coronary artery perfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The location of culprit coronary lesions can be inferred from the location of echocardiographic segmental abnormalities.",
"    <div class=\"footnotes\">",
"     LAD: left anterior descending artery; Prox: proximal; LCX: left circumflex artery; RCA: right coronary artery; PDA: posterior descending artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Feigenbaum, H, J Amer Soc Echo, 1988; 1:165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9301=[""].join("\n");
var outline_f9_5_9301=null;
var title_f9_5_9302="Multiple nerve plexuses A";
var content_f9_5_9302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Multiple nerve plexuses are found in the lower airways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A composite montage revealing the distribution of nerves and ganglia on the adventitial surface of a segmental bronchus of human fetal lung. Nerves were stained with antisera to protein gene product 9.5 (PGP 9.5). The adventitial nerve plexus can be found in both large and small airways. Parasympathetic ganglia are localized to the adventitial nerve plexus (arrow). Photomicrograph in the inset shows high power magnification of ganglion in the adventitial nerve plexus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sparrow MP, Weichselbaum M, McCray PB. Development of the innervation and airway smooth muscle in human fetal lung. Am J Respir Cell Mol Biol. 1999; 20:550.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9302=[""].join("\n");
var outline_f9_5_9302=null;
var title_f9_5_9303="Vulvar cancer: Clinical manifestations, diagnosis, and pathology";
var content_f9_5_9303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9303/contributors\">",
"     John C Elkas, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9303/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/5/9303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer is the fourth most common gynecologic cancer (following cancer of the uterine corpus, ovary, and cervix) and comprises 5 percent of malignancies of the female genital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/1\">",
"     1",
"    </a>",
"    ]. Annually in the United States, there are approximately 4700 new cases and 990 deaths from this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the rate of invasive vulvar carcinoma has remained stable over the past two decades, the incidence of in situ disease (vulvar intraepithelial neoplasia) has more than doubled.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, histology, and staging evaluation of women with vulvar cancer will be reviewed here. Treatment and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-adjusted incidence of vulvar cancer in the United States was 2.5 per 100,000 women, based upon 1997 to 2004 data from a national cancer database [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/2\">",
"     2",
"    </a>",
"    ]. Vulvar carcinoma is encountered most frequently in postmenopausal women. The mean age at diagnosis is 65, but may be falling. This was illustrated in a study of 78 women diagnosed with vulvar cancer between 1979 and 1993 in which the average age at presentation dropped from 69 to 55 during this interval [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for vulvar cancer include cigarette smoking, vulvar dystrophy (eg, lichen sclerosus), vulvar or cervical intraepithelial neoplasia, human papillomavirus (HPV) infection, immunodeficiency syndromes, a prior history of cervical cancer, and northern European ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two independent pathways of vulvar carcinogenesis are felt to currently exist, the first related to mucosal HPV infection and the second related to chronic inflammatory (vulvar dystrophy) or autoimmune processes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/6\">",
"     6",
"    </a>",
"    ]. HPV has been shown to be responsible for 60 percent of vulvar cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/7\">",
"     7",
"    </a>",
"    ]. Specifically, HPV 16 and 33 are the predominant subtypes accounting for 55.5 percent of all HPV-related vulvar cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increasing incidence of HPV-related vulvar intraepithelial neoplasia among young women may account for the fall in mean age of diagnosis of vulvar cancer discussed above. HPV DNA is found more commonly in vulvar cancers of young women who smoke as compared to older nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/7\">",
"     7",
"    </a>",
"    ]. Early detection and treatment of vulvar intraepithelial neoplasia may prevent the development of cancer. This may explain why the incidence of invasive vulvar cancer has remained stable even though the incidence of vulvar intraepithelial neoplasia has increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of all histological types of vulvar malignancy are similar. Most patients present with a unifocal vulvar plaque, ulcer, or mass (fleshy, nodular, or warty) on the labia majora; the labia minora, perineum, clitoris, and mons are less frequently involved (",
"    <a class=\"graphic graphic_picture graphicRef61663 \" href=\"UTD.htm?13/2/13348\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71378 \" href=\"UTD.htm?2/15/2293\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50426 \" href=\"UTD.htm?6/30/6629\">",
"     picture 3",
"    </a>",
"    ). In 10 percent of cases, the lesion is too extensive to determine the actual site of origin (",
"    <a class=\"graphic graphic_picture graphicRef64265 \" href=\"UTD.htm?40/24/41348\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions are multifocal in 5 percent of cases; thus, all vulvar and perianal skin surfaces, as well as the cervix and vagina, should be evaluated. A synchronous second malignancy, most commonly cervical neoplasia, is found in up to 22 percent of patients with a vulvar malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pruritus is a common complaint associated with most vulvar disorders; it is especially prevalent when there is an underlying vulvar dystrophy (eg, lichen sclerosus or squamous cell hyperplasia). We biopsy patients with lichen sclerosus if there is a suspicious lesion or the lesions are refractory to topical therapy.",
"   </p>",
"   <p>",
"    Vulvar bleeding or discharge, dysuria, or an enlarged lymph node in the groin are less frequently encountered symptoms, and suggestive of advanced disease. On the other hand, many patients are asymptomatic at the time of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=see_link\">",
"     \"Dermatitis of the vulva\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer is a histologic diagnosis made based upon a vulvar biopsy.",
"   </p>",
"   <p>",
"    Visual inspection of the vulva is performed based upon vulvar complaints or during a routine pelvic examination. Findings that are suspicious for preinvasive or invasive vulvar disease include any lesion that is raised or fungating as well as pigmented areas. If a lesion is not grossly evident, but there is clinical suspicion of vulvar neoplasia, a five percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    solution should be applied and the vulva examined with direct visual inspection and using a colposcope (or a handheld magnifying glass if a colposcope is not available). The concentrated acetic acid solution should be applied copiously with prolonged contact to the keratinized vulvar squamous epithelium. This allows the cells to fully dehydrate and will define acetowhite lesions and their underlying vascular changes. Acetowhite areas with abnormal vascular patterns should be biopsied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All areas of concern should be individually biopsied as cancer may be seen in areas with multifocal vulvar intraepithelial neoplasia. The biopsy should be taken from the area(s) of the lesion that appears most abnormal. If multiple abnormal areas are present, then multiple biopsies should be taken to \"map\" all potential sites of vulvar pathology. Pathologic evaluation may not be possible for specimens taken from areas of extensive necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis includes epidermal inclusion cysts, lentigos, disorders of Bartholin gland, acrochordons, seborrheic keratoses, hidradenomas, lichen sclerosus and other dermatoses, and condyloma acuminata. If one of these disorders is initially suspected but does not respond to appropriate treatment, biopsy should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vulvar cancers are squamous cell carcinomas; other histologies include melanoma, Bartholin gland adenocarcinoma, sarcoma, Paget disease, or basal cell carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of vulvar malignancies are squamous cell carcinomas. There are two subtypes, both of which usually occur on the labia or vestibule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The keratinizing, differentiated, or simplex type is more common, occurs in older women, is not related to HPV infection, but is associated with vulvar dystrophies such as lichen sclerosus and, in developing countries, chronic venereal granulomatous disease.",
"     </li>",
"     <li>",
"      The classic, warty, or Bowenoid type is predominantly associated with HPV 16, 18, and 33, and found in younger women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Risk factors associated with HPV infection include early age at first intercourse, multiple sexual partners, human immunodeficiency virus (HIV) infection, and cigarette smoking. These women tend to present with early stage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/13\">",
"       13",
"      </a>",
"      ], although several cases of stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      disease in HIV infected women have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cervical cancer is also strongly linked to persistent HPV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/15\">",
"     15",
"    </a>",
"    ]. Moreover, there is evidence that some high grade vulvar and vaginal intraepithelial neoplasia is a monoclonal lesion derived from high grade or malignant cervical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/16\">",
"     16",
"    </a>",
"    ]. Presence of the cervix does not appear to be necessary for oncogenic HPV to infect the genital tract. The prevalence of oncogenic HPV subtypes in the vagina is similar in women who have and have not undergone hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Verrucous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Verrucous carcinoma is a variant of squamous cell cancer that has distinctive features. Although cauliflower-like in appearance, it is differentiated from squamous cell carcinoma with a verrucous configuration by biopsy of the lesion base, which shows papillary fronds without the central connective tissue core typical of condylomata acuminata. The lesion grows slowly and rarely metastasizes to lymph nodes, but it may be locally destructive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the second most common vulvar cancer histology, accounting for approximately 5 to 10 percent of primary vulvar neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Melanoma of the vulva occurs predominantly in postmenopausal white non-Hispanic women, at a median age of 68 years (range 10 to 99 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, cutaneous melanomas presenting at other sites often develop before age 45. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5112797#H5112797\">",
"     \"Risk factors for the development of melanoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a United States national cancer database from 1985 to 1994, female genital tract lesions comprised 0.02 percent of all melanomas and 18 percent of mucosal melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar melanoma is usually a pigmented lesion, but amelanotic lesions also occur. Most arise de novo on the clitoris or labia minora, but can also develop within preexisting junctional or compound nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar melanoma is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Basal cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two percent of vulvar cancers are basal cell cancers and 2 percent of basal cell cancers occur on the vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/24\">",
"     24",
"    </a>",
"    ]. They usually affect postmenopausal Caucasian women and may be locally invasive, although usually nonmetastasizing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. The typical appearance is that of a \"rodent\" ulcer with rolled edges and central ulceration; the lesion may be pigmented or pearly and gray. They are often asymptomatic, but pruritus, bleeding, or pain may occur.",
"   </p>",
"   <p>",
"    Basal cell carcinomas are associated with a high incidence of antecedent or concomitant malignancy elsewhere in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, a thorough search for other primary malignancies should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas (including leiomyosarcomas, rhabdomyosarcomas, liposarcomas, angiosarcomas, neurofibrosarcomas, fibrous histiocytomas, and epithelioid sarcomas) constitute 1 to 2 percent of vulvar malignancies. The prognosis is generally poor. As with soft tissue sarcomas located elsewhere on the extremities and trunk, high-grade lesions that are larger than 5 cm in diameter, with infiltrating margins and a high mitotic rate are those most likely to recur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Extramammary Paget disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extramammary Paget disease, an intraepithelial adenocarcinoma, accounts for less than 1 percent of all vulvar malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/26\">",
"     26",
"    </a>",
"    ]. Most patients are in their 60s and 70s and Caucasian.",
"   </p>",
"   <p>",
"    Pruritus is the most common symptom, present in 70 percent of patients. Vulvar Paget disease is similar in appearance to Paget disease of the breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    .) The lesion has an eczematoid appearance; it is well-demarcated and has slightly raised edges and a red background, often dotted with small, pale islands. It is usually multifocal and may occur anywhere on the vulva, mons,",
"    <span class=\"nowrap\">",
"     perineum/perianal",
"    </span>",
"    area, or inner thigh.",
"   </p>",
"   <p>",
"    Differential diagnosis includes melanoma, leukoplakia, basal cell or squamous cell carcinoma, condyloma acuminata, hidradenitis suppurativa, psoriasis, fungal infection, seborrheic or contact dermatitis, and lichen sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is based upon characteristic histopathology (",
"    <a class=\"graphic graphic_picture graphicRef62814 graphicRef77680 \" href=\"UTD.htm?5/44/5834\">",
"     picture 5A-B",
"    </a>",
"    ). Vulvar biopsy should be performed in patients with suspicious lesions, including those with persistent pruritic eczematous lesions that fail to resolve within six weeks of appropriate antieczema therapy.",
"   </p>",
"   <p>",
"    Invasive adenocarcinomas may be present within or beneath the surface lesion (4 to 17 percent in two series totaling 176 patients) (",
"    <a class=\"graphic graphic_picture graphicRef69564 graphicRef81965 \" href=\"UTD.htm?43/44/44745\">",
"     picture 6A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Women with Paget disease of the vulva should also be evaluated for the possibility of synchronous neoplasms, as approximately 20 to 30 percent of these patients have a noncontiguous carcinoma (eg, involving breast, rectum, bladder, urethra, cervix, or ovary) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bartholin gland adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a rare malignancy, most primary adenocarcinomas of the vulva occur in the Bartholin gland. This gland is composed of columnar epithelium; ducts are lined by stratified squamous epithelium which changes to transitional cell epithelium as the terminal ducts are reached. Cancers arising in Bartholin gland are most often adenocarcinomas or squamous cell carcinomas, but transitional cell carcinomas, adenosquamous, and adenoid cystic carcinomas may also develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Only the squamous cell lesions are related to HPV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median age at diagnosis of Bartholin gland cancer is 57. Bartholin gland tumors are usually solid and infiltrate deep into the vulva. Enlargement of the Bartholin gland in a postmenopausal woman is worrisome for malignancy since benign inflammatory disease usually does not occur in this age group. The gland should be biopsied in older (over 40 years of age) women with a mass in this location, even if the lesion appears cystic or abscessed.",
"   </p>",
"   <p>",
"    Metastatic disease is common in cancers of Bartholin gland because of the rich vascular and lymphatic network in this area. In one series of 11 women with Bartholin gland cancer, 55 percent developed recurrent disease, and 67 percent were alive at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/32\">",
"     32",
"    </a>",
"    ]. The only two patients with isolated vulvar recurrence were alive without disease at 8 and 180 months, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MODE OF SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar carcinoma metastasizes by a variety of mechanisms. Understanding these potential pathways is important for the evaluation and treatment of these tumors. Modes of spread include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct extension to adjacent structures (eg, vagina, urethra, clitoris, anus).",
"     </li>",
"     <li>",
"      Lymphatic embolization to regional lymph nodes can occur early in the course of disease, even in patients with small lesions. In one report, approximately 10 percent of superficially invasive vulvar cancers (ie, lesions with &gt;1 but less than 3 mm of stromal invasion) had lymph node metastases at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/33\">",
"       33",
"      </a>",
"      ]. Most vulvar cancers spread first to the groin (inguinal-femoral) lymph nodes, which is why these nodes are sampled as part of staging. Lesions that are on one side of the vulva generally spread only to the ipsilateral groin nodes.",
"     </li>",
"     <li>",
"      Hematogenous dissemination, which typically occurs late in the course of the disease, is rare in patients without inguinofemoral lymph node involvement. In one series, patients with fewer than three positive lymph nodes at the time of initial diagnosis had a significantly lower risk of hematogenous spread as compared to those with three or more positive lymph nodes (4 versus 66 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9303/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvar pruritus is the most common symptom of vulvar cancer and a unifocal vulvar nodule, plaque, ulcer, or mass (fleshy, nodular, or warty) on the labia majora is the most common physical finding. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is based upon results of biopsy. We recommend that the biopsy be taken from the center of the lesion because those taken from the leading edge may not reflect the most severe histology of the lesion. If multiple abnormal areas are present, then multiple biopsies should be taken to \"map\" all potential sites of vulvar pathology. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a lesion is not grossly evident but clinical suspicion is high because of chronic pruritus of uncertain etiology, we suggest colposcopic examination of the vulva be performed with biopsy of suspicious areas.",
"     </li>",
"     <li>",
"      If a benign lesion of the vulva is initially suspected, but does not respond to standard treatment, biopsy is recommended to exclude malignancy and establish a diagnosis. Both squamous cell and verrucous carcinoma may resemble benign condyloma acuminatum and extramammary Paget disease may resemble vulvar dermatoses.",
"     </li>",
"     <li>",
"      Ninety percent of vulvar cancers are squamous cell carcinomas. In premenopausal women these cancers are often associated with HPV 16, 18, or 33 infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Melanoma is the second most common type of vulvar cancer. Lesions typically arise de novo on the clitoris or labia minora, but can also develop within preexisting junctional or compound nevi. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extramammary Paget disease and basal cell carcinomas are associated with a high incidence of antecedent or concomitant malignancy elsewhere in the body. Therefore, we suggest assessment for synchronous neoplasms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Extramammary Paget disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Basal cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/2\">",
"      Bodelon C, Madeleine MM, Voigt LF, Weiss NS. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control 2009; 20:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/3\">",
"      Messing MJ, Gallup DG. Carcinoma of the vulva in young women. Obstet Gynecol 1995; 86:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/4\">",
"      Ansink A. Vulvar squamous cell carcinoma. Semin Dermatol 1996; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/5\">",
"      Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 2008; 122:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/6\">",
"      de Koning MN, Quint WG, Pirog EC. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. Mod Pathol 2008; 21:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/7\">",
"      Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 1995; 85:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/8\">",
"      Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/9\">",
"      Zacur H, Genadry R, Woodruff JD. The patient-at-risk for development of vulvar cancer. Gynecol Oncol 1980; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/10\">",
"      Collins CG, Lee FY, Roman-Lopez JJ. Invasive carcinoma of the vulva with lymph node metastasis. Am J Obstet Gynecol 1971; 109:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/11\">",
"      Hildesheim A, Han CL, Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997; 90:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/12\">",
"      Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction. Obstet Gynecol 1997; 89:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/13\">",
"      Al-Ghamdi A, Freedman D, Miller D, et al. Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 2002; 84:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/14\">",
"      Elit L, Voruganti S, Simunovic M. Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. Gynecol Oncol 2005; 98:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/15\">",
"      Bosch FX, Manos MM, Mu&ntilde;oz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/16\">",
"      Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005; 97:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/17\">",
"      Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/18\">",
"      Piura B, Rabinovich A, Dgani R. Basal cell carcinoma of the vulva. J Surg Oncol 1999; 70:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/19\">",
"      Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 1992; 50:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/20\">",
"      Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007; 110:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/21\">",
"      Stang A, Streller B, Eisinger B, J&ouml;ckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005; 96:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/22\">",
"      Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.",
"     </a>",
"    </li>",
"    <li>",
"     and Practice of Gynecologic Oncology, 2nd, Hoskins WJ, Perez CA, Young RC (Eds), Lippincott-Raven, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/24\">",
"      de Giorgi V, Salvini C, Massi D, et al. Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecol Oncol 2005; 97:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/25\">",
"      Benedet JL, Miller DM, Ehlen TG, Bertrand MA. Basal cell carcinoma of the vulva: clinical features and treatment results in 28 patients. Obstet Gynecol 1997; 90:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/26\">",
"      Parker LP, Parker JR, Bodurka-Bevers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 2000; 77:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/27\">",
"      Shepherd V, Davidson EJ, Davies-Humphreys J. Extramammary Paget's disease. BJOG 2005; 112:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/28\">",
"      Fanning J, Lambert HC, Hale TM, et al. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Am J Obstet Gynecol 1999; 180:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/29\">",
"      Feuer GA, Shevchuk M, Calanog A. Vulvar Paget's disease: the need to exclude an invasive lesion. Gynecol Oncol 1990; 38:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/30\">",
"      Felix JC, Cote RJ, Kramer EE, et al. Carcinomas of Bartholin's gland. Histogenesis and the etiological role of human papillomavirus. Am J Pathol 1993; 142:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/31\">",
"      Copeland LJ, Sneige N, Gershenson DM, et al. Bartholin gland carcinoma. Obstet Gynecol 1986; 67:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/32\">",
"      Cardosi RJ, Speights A, Fiorica JV, et al. Bartholin's gland carcinoma: a 15-year experience. Gynecol Oncol 2001; 82:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/33\">",
"      Hacker NF, Nieberg RK, Berek JS, et al. Superficially invasive vulvar cancer with nodal metastases. Gynecol Oncol 1983; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9303/abstract/34\">",
"      Hacker NF, Berek JS, Lagasse LD, et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 1983; 61:408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3237 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9303=[""].join("\n");
var outline_f9_5_9303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOLOGIC TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Verrucous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Extramammary Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bartholin gland adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MODE OF SPREAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3237|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/2/13348\" title=\"picture 1\">",
"      Vulvar cancer 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2293\" title=\"picture 2\">",
"      Vulvar cancer 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/30/6629\" title=\"picture 3\">",
"      Vulvar cancer 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/24/41348\" title=\"picture 4\">",
"      Vulvar cancer 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/17/29974\" title=\"picture 5A\">",
"      Extramammary Pagets disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/61/23509\" title=\"picture 5B\">",
"      Extramammary Paget disease2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35510\" title=\"picture 6A\">",
"      Pagets dis with carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/28/29124\" title=\"picture 6B\">",
"      Pagets dis with carcinoma2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=related_link\">",
"      Dermatitis of the vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9304="Biology of glomerular podocytes";
var content_f9_5_9304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology of glomerular podocytes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9304/contributors\">",
"     Pierre Ronco, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9304/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9304/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/5/9304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The healthy kidney filters metabolic byproducts into the urine but prevents the passage of albumin and other larger essential molecules. This selective filtration occurs across the glomerular capillary wall:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Under normal circumstances, the glomerular capillary wall is extremely permeable to water and small solutes, but negligibly to albumin or other proteins of equivalent molecular weight or larger.",
"     </li>",
"     <li>",
"      Defects in the glomerular capillary wall result in increased permeability to albumin and proteins of similar size or even larger, causing proteinuria.",
"     </li>",
"     <li>",
"      Electrical potential differences generated by transglomerular flow may modulate the flux of anionic (charged) albumin across the glomerular capillary wall [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The traditional view that the glomerular capillary wall hinders the transit of protein is largely based upon micropuncture studies that demonstrated very low concentrations of albumin in Bowman's space in non-nephrotic animals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This view has been challenged by newer data that have demonstrated by intravital 2-photon microscopy, much higher concentrations of albumin in Bowman's space than were reported previously [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/4\">",
"     4",
"    </a>",
"    ]. Given the novelty of the technique of intravital 2-photon microscopy, these observations need to be validated in other systems and species, especially since they substantially alter our understanding of the pathogenesis of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known, however, why the filter does not routinely clog with large proteins that enter the glomerular basement membrane (GBM). It has been hypothesized that proteins cross the GBM mainly by diffusion rather than by liquid flow, whereas water crosses entirely by flow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/8\">",
"     8",
"    </a>",
"    ]. An active transport that removes immunoglobulins that accumulate at the filtration barrier has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/9\">",
"     9",
"    </a>",
"    ]. This transport involves the neonatal Fc receptor (FcRn). In a murine model, IgG accumulated in the GBM of FcRn-deficient mice as they aged, and tracer studies showed delayed clearance of IgG from the kidneys of FcRn-deficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/9\">",
"     9",
"    </a>",
"    ]. Genetic or acquired impairment of the clearance machinery may be a common mechanism promoting glomerular diseases.",
"   </p>",
"   <p>",
"    Over the last decade, studies among patients with hereditary proteinuric syndromes have markedly advanced our knowledge of the structure and composition of the glomerular capillary wall and the changes in its composition that lead to proteinuria. However, the changes in the glomerular capillary wall that underlie proteinuria in hereditary diseases do not necessarily account for the proteinuria that accompanies acquired causes of nephrotic syndrome, which are much more common. Thus, the underlying molecular mechanisms of acquired proteinuric diseases remain less well characterized.",
"   </p>",
"   <p>",
"    It is increasingly appreciated that defects in podocyte structure and function result in increased glomerular permeability. This topic review will focus primarily on the biology of glomerular podocytes and defects in podocyte structure that appear to underlie many proteinuric renal diseases.",
"   </p>",
"   <p>",
"    Reviews of clinical proteinuria, including causes, manifestations, and treatment of specific glomerular disease, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOMERULAR CAPILLARY WALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;To better appreciate the biology of glomerular podocytes, it is important to understand the structural and functional anatomy of the glomerular capillary wall.",
"   </p>",
"   <p>",
"    The glomerular capillary wall, through which the filtrate must pass, consists of the following three layers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fenestrated capillary endothelium, extensively coated with a layer of polyanionic glycosoaminoglycans and glycoproteins.",
"     </li>",
"     <li>",
"      Glomerular basement membrane (GBM), containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      sulfate and other anionic glycosoaminoglycans.",
"     </li>",
"     <li>",
"      Podocytes (or epithelial cells), which are attached to the GBM by discrete foot processes. The pores between the foot processes (slit pores) are closed by a thin membrane called the slit diaphragm, which functions as a modified adherens junction and may also be permeated by anatomical pores [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Defects in any of the three components of the glomerular capillary wall can lead to proteinuria (",
"    <a class=\"graphic graphic_picture graphicRef50018 \" href=\"UTD.htm?22/35/23091\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In addition, cross-talk between podocytes and endothelial and mesangial cells are key to the maintenance of glomerular capillary wall function. As examples, the production of vascular endothelial growth factor (VEGF) by podocytes is necessary for the integrity of the glomerular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/14\">",
"     14",
"    </a>",
"    ], and the upregulation and secretion of the podocyte protein, angiopoietin-like-4 (Angptl4) into the glomerular capillary wall causes marked proteinuria in experimental models of nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PODOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podocytes are terminally differentiated epithelial cells that have large cell bodies and long primary or major processes. The primary processes attach to the underlying GBM via multiple foot processes. Adhesion molecules, such as alpha3beta1 integrin complex and dystroglycan (which are present on the basal membrane of foot processes), attach the podocyte to the GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Slit diaphragm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interdigitating foot processes of adjacent podocytes are joined laterally by slit diaphragms that bridge the intervening filtration slits. The following proteins have been found to comprise the slit diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neph1 and Neph2 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      FAT1 and FAT 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Podocin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transient receptor potential cation channel 6 (TRPC6) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tight junction proteins, including junctional adhesion molecule A, occludin and cingulin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Slit diaphragms interact with the actin cytoskeleton of podocyte foot processes via linker proteins. These include CD2-associated protein (CD2AP) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], Nck [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], zona occludens-1, and the catenins. Selective deletion of Nck expression in podocytes of adult mice rapidly leads to proteinuria, glomerulosclerosis, and altered morphology of foot processes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/33\">",
"     33",
"    </a>",
"    ]. Mutations of some of the genes that encode slit diaphragm proteins cause rearrangement of the actin cytoskeleton, which results in foot process effacement and proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrin and Neph1 also interact directly with the Par3-aPKC protein complex at the podocyte intercellular junction, suggesting that this complex plays a key role in the establishment and maintenance of podocyte polarity as it does in other polarized epithelia and neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reviews of the evidence showing that abnormalities of these proteins are causative in some congenital disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Actin cytoskeleton",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podocyte architecture is maintained by a contractile apparatus composed of microfilaments comprising actin, type I and type II myosins, alpha-actinin, talin, paxillin, and vinculin, and palladin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This cytoskeleton helps to support the glomerular capillary wall, which is subject to the high hydrostatic pressure necessary for glomerular filtration and plays a key role in the foot process architecture (",
"    <a class=\"graphic graphic_figure graphicRef50016 \" href=\"UTD.htm?12/57/13207\">",
"     figure 1",
"    </a>",
"    ). The actin cytoskeleton also contributes to the highly motile character of these specialized cells.",
"   </p>",
"   <p>",
"    Immunofluorescence and confocal microscopy have demonstrated two distinct actin cytoskeletal networks present in the foot processes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dense actin bundles are present above the level of the slit diaphragm and extend parallel to the longitudinal axis.",
"     </li>",
"     <li>",
"      A cortical actin network extends just below the plasma membrane of the foot processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different actin-binding proteins are associated with each of these networks. Thus, whereas alpha-actinin and synaptopodin are associated with the actin bundles above the slit diaphragm, the cortical actin network co-localizes with cortactin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Foot process effacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flattening of foot processes or foot process effacement is a characteristic histologic finding associated with most primary and secondary glomerular diseases. Rearrangement of the actin cytoskeleton is necessary for foot process effacement to occur and stabilization of the actin cytoskeleton decreases proteinuria. The actin cytoskeleton is a fluid structure that can be quickly and reversibly reorganized. It is a direct target of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A, which is an effective treatment for reducing nephrotic range proteinuria among patients with minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/40\">",
"     40",
"    </a>",
"    ]. The effect of cyclosporine A on the cytoskeleton is independent of (though does not exclude) its effect on T cell dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Actin is normally organized into coordinated stress fibers in mature foot processes. Podocyte injury causes the rearrangement of actin to a dense network [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytoskeleton can be altered by at least four different mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct injury of podocytes can occur by systemic or locally produced toxins (ie, reactive oxygen species), viral infection, drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      , interferon) or local activation of the renin angiotensin system [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities of cytoskeletal structural proteins can adversely affect cytoskeletal dynamics. An example is mutations of alpha-actinin-4, which cause hereditary focal segmental glomerular sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/42\">",
"       42",
"      </a>",
"      ]. This abnormality increases the affinity of alpha-actinin-4 for actin, which may alter cytoskeletal fluidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The disruption of myosin 1e in mice promotes podocyte injury with foot process effacement [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/43\">",
"       43",
"      </a>",
"      ]. Genetic variations in the MYH9 locus are associated with progressive nondiabetic proteinuric kidney disease in African Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. MYH9 encodes nonmuscle myosin heavy chain type II isoform A, expressed by podocytes and other cells in the kidney. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Injury to the slit diaphragm, arising from congenital or acquired disorders, can initiate abnormal actin and nephrin signaling, resulting in cytoskeletal reorganization [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/11,16-18,21,22,46\">",
"       11,16-18,21,22,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in the structure of the GBM may lead to cytoskeletal derangements, as observed in laminin beta 2 deficient mice, in which proteinuria precedes foot process effacement [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Direct podocyte injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podocytes may be direct targets of injury in acquired proteinuric diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/48\">",
"     48",
"    </a>",
"    ]. Injury may be immunologic or non-immunologic. An example of an immunologic cause of podocyte injury is the effect of interleukin-13 (IL-13) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Accumulating data have suggested that IL-13 is a permeability factor that causes minimal change disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .) Isolated human and rat glomeruli and cultured human and rat podocytes express receptors for IL-13, and the exposure of cells to IL-13 initiates intracellular signaling, changes in transepithelial resistance, and changes in protein trafficking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These data suggest that a direct effect of IL-13 on podocytes may underlie minimal change disease.",
"   </p>",
"   <p>",
"    Non-immunologic causes of podocyte injury include viral infection (specifically HIV), drug toxicity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ), local activation of the renin-angiotensin system (RAS), and reactive oxygen species (ROS).",
"   </p>",
"   <p>",
"    HIV nephropathy is characterized by collapsing focal segmental glomerulosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical studies and animal models have shown that the podocyte is directly infected by HIV genes and may provide a reservoir for replicating virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Exogenous expression of HIV genes, Nef and Vpr, causes dedifferentiation, proliferation and loss of contact inhibition, and apoptosis of podocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. Some believe that parvo B19 virus may have similar toxic effects as HIV on podocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of systemic RAS limits the progression of chronic kidney disease in the setting of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/59\">",
"     59",
"    </a>",
"    ]. This is due, in part, to a reduction of transglomerular pressure. However, locally produced angiotensin may also have direct toxic effects on the podocyte. Angiotensin receptors -1 and -2 are expressed by podocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/60\">",
"     60",
"    </a>",
"    ]. Mechanical strain of cultured podocytes increases expression of the angiotensin receptor-1 as well as angiotensin-II and enhances podocyte apoptosis, which is abrogated by angiotensin receptor blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, a transgenic rat that overexpresses the angiotensin receptor-1, specifically in podocytes, is characterized by proteinuria and structural changes in the podocyte that include effacement and detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactive oxygen species are produced in a number of conditions including puromycin aminonucleoside nephrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/62\">",
"     62",
"    </a>",
"    ], complement activation, and metabolic disorders such as obesity. In obese patients that are prone to develop focal segmental glomerulosclerosis, albuminuria is negatively correlated with plasma adiponectin, while adiponectin knock-out mice exhibit albuminuria and effacement of podocyte foot processes. The protective effect of adiponectin seems to occur through activation of adiponectin receptors expressed on the podocyte membrane and reduction of oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of signaling pathways may lead to podocyte injury and proteinuria. In human proteinuric kidney diseases such as diabetic nephropathy and focal segmental glomerulosclerosis, upregulation of Wnt1 and active beta-catenin is observed in podocytes, while podocyte-specific knock-out of beta-catenin protects against development of albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/64\">",
"     64",
"    </a>",
"    ]. Podocytes possess the complete machinery for glutamatergic signaling, and derangements in that signaling may lead to proteinuric kidney diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/65\">",
"     65",
"    </a>",
"    ]. The Notch pathway seems to be involved in the development of proteinuria because Notch intracellular domain is detected in injured podocytes and genetic inactivation or pharmacologic inhibition of Notch ameliorates proteinuria and podocyte damage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Podocyte-specific deletion of Dicer, an enzyme that generates microRNA (small, noncoding RNA that function as important regulators of gene expression) alters cytoskeletal dynamics, and induces proteinuria and glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Podocyte depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in podocyte number resulting from apoptosis or detachment from the GBM may contribute to proteinuria and progressive glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. In many glomerular disorders that are characterized by hypertrophy, the volume of the glomerular tuft increases, despite the decrease in podocyte number [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/71\">",
"     71",
"    </a>",
"    ]. The resulting decrease in podocyte density causes areas of denuded GBM, which are foci for adhesions to parietal epithelial cells and eventual crescent formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cytoskeletal rearrangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which podocyte injury or mutations in genes for slit diaphragm proteins initiate rearrangement of the cytoskeleton is unclear. Similar intracellular events, such as phosphorylation of constituent proteins, appear to occur during development of the foot processes and after podocyte injury. During podocyte differentiation, for example, nephrin is transiently phosphorylated on multiple tyrosine residues by the Src family kinase, Fyn [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/31\">",
"     31",
"    </a>",
"    ]. Phosphorylation of nephrin allows its interaction with Nck, which is required for actin reorganization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/73\">",
"     73",
"    </a>",
"    ]. Decreased nephrin phosphorylation may occur following podocyte injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible mechanism of cytoskeletal rearrangement is via the degradation of dynamin, a GTPase protein that is generally considered to have a key role in deforming cellular membranes. Dynamin associates with actin, possibly via the actin-binding protein, cortactin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cleavage of dynamin by cathepsin-L may initiate reorganization of the cytoskeleton, resulting in clinical disease. Support for this is provided by findings in animal models and some human glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef70765 \" href=\"UTD.htm?19/50/20259\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of cathepsin-L were found to be increased in a murine model of minimal change disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/76\">",
"       76",
"      </a>",
"      ]. This increase has also been observed in patients with membranous nephropathy, focal segmental glomerulosclerosis, and diabetic nephropathy, although significant increases were not found in those with other proteinuric kidney diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Proteinuria and foot process effacement induced by lipopolysaccharide are abrogated in cathepsin-L-knockout mice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whereas the expression of a cathepsin-L-degraded dynamin fragment causes foot process effacement and proteinuria, the expression of cathepsin-L-resistant dynamin mutants decreases proteinuria .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytoskeletal rearrangement may also be induced by the urokinase receptor (uPAR) via its activation of the vitronectin receptor, alphavbeta3 integrin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/78\">",
"     78",
"    </a>",
"    ]. The absence of uPAR, beta3 integrin or the alphavbeta3 integrin ligand, vitronectin, protects mice from developing lipopolysaccharide-induced proteinuria. This protection is abolished by exogenous expression of either uPAR or a constitutively active beta3 integrin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/78\">",
"     78",
"    </a>",
"    ]. uPAR may be required to activate alphavbeta3 integrin in podocytes promoting cell motility and activation of small GTPases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Proteinuria as a toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although massive proteinuria may occur in the absence of obvious structural change in the slit diaphragm and foot processes, sustained proteinuria event is invariably eventually associated with foot process effacement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/47,79-82\">",
"     47,79-82",
"    </a>",
"    ]. The mechanism underlying this phenomenon is unclear. One possibility is that exposure of podocytes to an increased concentration of albumin and IgG is sufficient to induce changes in the cytoskeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9304/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The glomerular capillary wall consists of the fenestrated capillary endothelium, glomerular basement membrane (GBM), and glomerular podocytes (or epithelial cells). Defects in any of the three components of the glomerular capillary wall can lead to proteinuria. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glomerular capillary wall'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glomerular podocytes are terminally differentiated epithelial cells that have large cell bodies and long primary or major processes. The primary processes attach to the underlying GBM via multiple foot processes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Podocytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The interdigitating foot processes of adjacent podocytes are joined laterally by slit diaphragms that bridge the intervening filtration slits. A number of proteins have been found to comprise the slit diaphragm; these include nephrin, neph1, neph2, FAT1, FAT 2, podocin, TRPC6 and tight junction proteins. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Slit diaphragm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foot process effacement of glomerular podocytes is a characteristic histologic finding associated with glomerular diseases affecting the podocyte. Rearrangement of the actin cytoskeleton is necessary for foot process effacement to occur. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Foot process effacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible molecular mechanisms underlying cytoskeletal rearrangement include",
"      <span class=\"nowrap\">",
"       phosphorylation/dephosphorylation",
"      </span>",
"      of nephrin and cleavage of dynamin (a GTPase protein) by cathepsin-L. Activation of the urokinase receptor (uPAR) and initiation of beta3 integrin signaling may also be involved (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Cytoskeletal rearrangement'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/1\">",
"      Hausmann R, Kuppe C, Egger H, et al. Electrical forces determine glomerular permeability. J Am Soc Nephrol 2010; 21:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/2\">",
"      Oken DE, Flamenbaum W. Micropuncture studies of proximal tubule albumin concentrations in normal and nephrotic rats. J Clin Invest 1971; 50:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/3\">",
"      Tojo A, Endou H. Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol 1992; 263:F601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/4\">",
"      Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/5\">",
"      Gekle M. Renal albumin handling: a look at the dark side of the filter. Kidney Int 2007; 71:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/6\">",
"      Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006; 69:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/7\">",
"      Comper WD, Haraldsson B, Deen WM. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 2008; 19:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/8\">",
"      Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci U S A 2003; 100:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/9\">",
"      Akilesh S, Huber TB, Wu H, et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A 2008; 105:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/10\">",
"      Gagliardini E, Conti S, Benigni A, et al. Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol 2010; 21:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/11\">",
"      Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 2006; 17:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/12\">",
"      Singh A, Satchell SC, Neal CR, et al. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 2007; 18:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/13\">",
"      Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/14\">",
"      Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/15\">",
"      Clement LC, Avila-Casado C, Mac&eacute; C, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/16\">",
"      Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/17\">",
"      Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/18\">",
"      Kestil&auml; M, Lenkkeri U, M&auml;nnikk&ouml; M, et al. Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/19\">",
"      Donoviel DB, Freed DD, Vogel H, et al. Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 2001; 21:4829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/20\">",
"      Sellin L, Huber TB, Gerke P, et al. NEPH1 defines a novel family of podocin interacting proteins. FASEB J 2003; 17:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/21\">",
"      Ihalmo P, Palm&eacute;n T, Ahola H, et al. Filtrin is a novel member of nephrin-like proteins. Biochem Biophys Res Commun 2003; 300:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/22\">",
"      Barletta GM, Kovari IA, Verma RK, et al. Nephrin and Neph1 co-localize at the podocyte foot process intercellular junction and form cis hetero-oligomers. J Biol Chem 2003; 278:19266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/23\">",
"      Ciani L, Patel A, Allen ND, ffrench-Constant C. Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol Cell Biol 2003; 23:3575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/24\">",
"      Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/25\">",
"      Reiser J, Polu KR, M&ouml;ller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/26\">",
"      Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/27\">",
"      Fukasawa H, Bornheimer S, Kudlicka K, Farquhar MG. Slit diaphragms contain tight junction proteins. J Am Soc Nephrol 2009; 20:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/28\">",
"      Schwarz K, Simons M, Reiser J, et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/29\">",
"      Huber TB, Kottgen M, Schilling B, et al. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001; 276:41543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/30\">",
"      Huber TB, Schermer B, M&uuml;ller RU, et al. Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A 2006; 103:17079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/31\">",
"      Verma R, Kovari I, Soofi A, et al. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/32\">",
"      Uchida K, Suzuki K, Iwamoto M, et al. Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int 2008; 73:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/33\">",
"      Jones N, New LA, Fortino MA, et al. Nck proteins maintain the adult glomerular filtration barrier. J Am Soc Nephrol 2009; 20:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/34\">",
"      Hartleben B, Schweizer H, L&uuml;bben P, et al. Neph-Nephrin proteins bind the Par3-Par6-atypical protein kinase C (aPKC) complex to regulate podocyte cell polarity. J Biol Chem 2008; 283:23033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/35\">",
"      Huber TB, Hartleben B, Winkelmann K, et al. Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol 2009; 20:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/36\">",
"      Hirose T, Satoh D, Kurihara H, et al. An essential role of the universal polarity protein, aPKClambda, on the maintenance of podocyte slit diaphragms. PLoS One 2009; 4:e4194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/37\">",
"      Faul C, Asanuma K, Yanagida-Asanuma E, et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/38\">",
"      Endlich N, Schordan E, Cohen CD, et al. Palladin is a dynamic actin-associated protein in podocytes. Kidney Int 2009; 75:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/39\">",
"      Ichimura K, Kurihara H, Sakai T. Actin filament organization of foot processes in rat podocytes. J Histochem Cytochem 2003; 51:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/40\">",
"      Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/41\">",
"      Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/42\">",
"      Michaud JL, Chaisson KM, Parks RJ, Kennedy CR. FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/43\">",
"      Krendel M, Kim SV, Willinger T, et al. Disruption of Myosin 1e promotes podocyte injury. J Am Soc Nephrol 2009; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/44\">",
"      Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/45\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/46\">",
"      Hussain S, Romio L, Saleem M, et al. Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol 2009; 20:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/47\">",
"      Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte abnormalities inLamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006; 116:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/48\">",
"      Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/49\">",
"      Van Den Berg JG, Aten J, Chand MA, et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 2000; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/50\">",
"      Van Den Berg JG, Aten J, Annink C, et al. Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 282:F26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/51\">",
"      Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/52\">",
"      Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/53\">",
"      Sunamoto M, Husain M, He JC, et al. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int 2003; 64:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/54\">",
"      He JC, Husain M, Sunamoto M, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004; 114:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/55\">",
"      Husain M, D'Agati VD, He JC, et al. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005; 19:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/56\">",
"      Zhong J, Zuo Y, Ma J, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 2005; 68:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/57\">",
"      Zuo Y, Matsusaka T, Zhong J, et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 2006; 17:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/58\">",
"      Shah SN, He CJ, Klotman P. Update on HIV-associated nephropathy. Curr Opin Nephrol Hypertens 2006; 15:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/59\">",
"      Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/60\">",
"      Sharma M, Sharma R, Greene AS, et al. Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol 1998; 274:F623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/61\">",
"      Hoffmann S, Podlich D, H&auml;hnel B, et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/62\">",
"      Mayrhofer C, Krieger S, Huttary N, et al. Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis. Am J Pathol 2009; 174:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/63\">",
"      Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645.",
"     </a>",
"    </li>",
"    <li>",
"     Dai, C, JASN 2009, doi: 10:10. 1681/ASN.20090 10019.",
"    </li>",
"    <li>",
"     Giardino, L, JASN 2009, doi: 10.1681/ASN.200812 1286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/66\">",
"      Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/67\">",
"      Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008; 19:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/68\">",
"      Shi S, Yu L, Chiu C, et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol 2008; 19:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/69\">",
"      Kim YH, Goyal M, Kurnit D, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/70\">",
"      Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/71\">",
"      Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/72\">",
"      Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/73\">",
"      Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/74\">",
"      Schafer DA. Regulating actin dynamics at membranes: a focus on dynamin. Traffic 2004; 5:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/75\">",
"      Merrifield CJ, Feldman ME, Wan L, Almers W. Imaging actin and dynamin recruitment during invagination of single clathrin-coated pits. Nat Cell Biol 2002; 4:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/76\">",
"      Reiser J, Oh J, Shirato I, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 2004; 279:34827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/77\">",
"      Sever S, Altintas MM, Nankoe SR, et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 2007; 117:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/78\">",
"      Wei C, M&ouml;ller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/79\">",
"      Topham PS, Kawachi H, Haydar SA, et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 1999; 104:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/80\">",
"      PIRANI CL, POLLAK VE, LANNIGAN R, FOLLI G. THE RENAL GLOMERULAR LESIONS OF PRE-ECLAMPSIA: ELECTRON MICROSCOPIC STUDIES. Am J Obstet Gynecol 1963; 87:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/81\">",
"      Good KS, O'Brien K, Schulman G, et al. Unexplained nephrotic-range proteinuria in a 38-year-old man: a case of \"no change disease\". Am J Kidney Dis 2004; 43:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/82\">",
"      Branten AJ, van den Born J, Jansen JL, et al. Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis. Kidney Int 2001; 59:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9304/abstract/83\">",
"      Morigi M, Buelli S, Angioletti S, et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005; 166:1309.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3091 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9304=[""].join("\n");
var outline_f9_5_9304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOMERULAR CAPILLARY WALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PODOCYTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Slit diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Actin cytoskeleton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Foot process effacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Direct podocyte injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Podocyte depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cytoskeletal rearrangement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Proteinuria as a toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3091|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/57/13207\" title=\"figure 1\">",
"      Actin signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/50/20259\" title=\"figure 2\">",
"      Glomerular structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3091|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/35/23091\" title=\"picture 1\">",
"      Electron micrograph of a normal glomerulus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9305="Spiculated cells (echinocytes and acanthocytes) and target cells";
var content_f9_5_9305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spiculated cells (echinocytes and acanthocytes) and target cells",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9305/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9305/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9305/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/5/9305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of morphologic alterations in red blood cells (RBCs) can be induced by changes in the cell membrane. Three of the most common variants, namely spiculated cells (echinocytes and acanthocytes) and target cells, will be discussed here. Other variants such as stomatocytes (hydrocytes) (",
"    <a class=\"graphic graphic_picture graphicRef75535 \" href=\"UTD.htm?8/51/9015\">",
"     picture 1",
"    </a>",
"    ) and xerocytes (dessicocytes) (",
"    <a class=\"graphic graphic_picture graphicRef62761 \" href=\"UTD.htm?3/30/3559\">",
"     picture 2",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"     \"Stomatocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=see_link\">",
"     \"Xerocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHINOCYTES AND ACANTHOCYTES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocytes and acanthocytes are two types of spiculated red blood cells. A freshly prepared peripheral blood smear is essential for distinguishing between these cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/1\">",
"     1",
"    </a>",
"    ]; wet preparations or scanning electron microscopy may also be useful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echinocytes (also called burr cells) have serrated edges over the entire surface of the cell and often appear crenated in a blood smear (",
"      <a class=\"graphic graphic_picture graphicRef62090 \" href=\"UTD.htm?17/63/18423\">",
"       picture 3",
"      </a>",
"      ). Although often confused with acanthocytes, the projections of the red cell membrane are smaller and much more uniform in shape and distribution in echinocytes.",
"     </li>",
"     <li>",
"      Acanthocytes (from the Greek acantha \"thorn\") have only a few spicules of varying size that project from the cell surface at irregular intervals (",
"      <a class=\"graphic graphic_picture graphicRef80080 \" href=\"UTD.htm?14/26/14760\">",
"       picture 4",
"      </a>",
"      ). They appear contracted and dense on stained peripheral blood smears. Spur cells appear to be the extreme form of acanthocytes and are seen in patients with severe liver disease (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Liver disease'",
"      </a>",
"      below). Spur cells are felt to be acanthocytes remodeled by the spleen, whereby the spicules become more blunt and the associated membrane loss makes the cell more spherocytic (spheroacanthocyte).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shape of these cells is thought to be related to changes in the organization of cell membrane components. In acanthocytes, this is often due to a defect in the lipid or protein composition of red cell red membrane. In a study of patients with chorea-acanthosis and McLeod syndrome, for example, acanthocytes had a greater tendency to form spikes than normal RBCs in an incubation system, indicating their weakness against membrane tension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/2\">",
"     2",
"    </a>",
"    ]. Focal changes in the membrane skeleton appeared to predispose to the acanthocyte phenotype. In one patient echinocytes were present in association with a massive splenic hemangioma and disappeared following splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hypothesis has been presented that implicates changes in the conformation in Band 3, a major component of the membrane skeleton, as the basis for acanthocyte formation in both congenital and acquired disorders in which these cells are found [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, echinocytes are easily produced in vitro and are often produced by a material in the patient's plasma that causes normal red cells to become echinocytic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echinocytes are often found as artifacts on blood smears. They can be produced in vitro by incubation at high pH or in the presence of high calcium concentrations, exposure to glass surfaces, reduced albumin concentrations, and after prolonged storage.",
"     </li>",
"     <li>",
"      Echinocytes have been demonstrated in both end-stage renal disease (in which incubation of echinocytic red cells in normal plasma leads to return of the normal discocytic shape) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/5\">",
"       5",
"      </a>",
"      ] and in liver disease. In the latter setting, an abnormal high-density lipoprotein binds to receptors on the outer surface of the red cell membrane and induces the characteristic conformational changes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with liver disease often have acanthocytes, echinocytes, and target cells on the peripheral blood smear (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Target cells'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These changes are most severe in advanced hepatocellular disease, which may be associated with 20 to 30 percent acanthocytes in the peripheral blood and moderate to severe hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spur cells are the extreme form of acanthocytes. They are probably acanthocytes that have been additionally remodeled by an enlarged spleen and considerably enriched in cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Increased red cell membrane proteolytic activity may also contribute to the formation of spur cells, a process that appears to be due in part to a circulating factor that is present in spur cell plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. A small study from Greece suggests that the presence of spur cell anemia in patients with alcoholic cirrhosis predicts for a shortened survival and aids in prioritization of such patients for liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acanthocyte results from a combination of abnormal surface area-to-volume ratio, the increase in cell membrane cholesterol characteristic of red cells in severe liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7\">",
"     7",
"    </a>",
"    ], impairment in membrane fluidity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7\">",
"     7",
"    </a>",
"    ], and an inability to remove and repair peroxidatively damaged fatty acids in the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulated fatty acid damage is a result of the adult red blood cell's inability to synthesize phospholipids de novo. However, the red cell can identify and remove peroxidized fatty acid chains that interfere with normal membrane lipid fluidity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/14\">",
"     14",
"    </a>",
"    ]. When the fatty acid is removed, a lyso-derivative remains. Since these lyso-derivatives are lytic, the missing fatty acid chain must be replaced. To accomplish this, the red cell depends upon its store of acyl groups that exists in the red cell membrane in the form of acylcarnitine. When needed, the fatty acid (acyl group) is transferred to acyl-CoA and the fatty acid is then inserted into the potentially lytic lysophospholipid by the enzyme lysophosphocholine acyl transferase (LAT).",
"   </p>",
"   <p>",
"    LAT is inhibited in spur red cells and can also be inhibited by heavily loading red cells with cholesterol in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, the excess red cell cholesterol in liver disease may be the first step in spur cell formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7,12,14\">",
"     7,12,14",
"    </a>",
"    ]. The second step involves extensive remodeling of the red cell in the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion, spur cell hemolytic anemia is severe enough to necessitate consideration of splenectomy. The operative morbidity in such cases is considerable, because the underlying alcoholism usually produces problems with thrombocytopenia and leukopenia, while the severity of the liver disease can cause problems with procoagulants and intolerance to anesthesia. Spur cell anemia resolves after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the pathogenesis of echinocytosis in liver disease appears to be different. An abnormal high-density lipoprotein binds to receptors on the outer surface of the red cell membrane and induces the characteristic conformational changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abetalipoproteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abetalipoproteinemia is characterized by the near absence of apolipoprotein B-containing lipoproteins in the plasma due to mutations in the gene for microsomal triglyceride transfer protein (MTP) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. As a result, absorption of lipids through the intestine is defective, serum cholesterol levels are extremely low, and serum beta lipoprotein is absent.",
"   </p>",
"   <p>",
"    A spectrum of clinical manifestations can be seen, depending upon the extent to which apolipoprotein B mediated metabolic processes are affected. All patients have neurologic manifestations (ataxia, retinitis pigmentosa) and acanthocytes; other manifestations include celiac syndrome and adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the abetalipoproteinemic acanthocytic red cell, the outer leaflet of the red cell membrane is enriched in sphingomyelin and cholesterol and the total red cell content of phosphatidyl choline is decreased by 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These lipid abnormalities are thought to explain acanthocyte formation, apparently via an excess of surface area in the outer leaflet compared to the inner leaflet of the membrane bilayer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The red cell shape defect is not present in young cells but accumulates with cell aging. In severe cases, 50 to 90 percent of the red cells are acanthocytes. Despite the profound morphologic abnormality, patients with this disorder are not anemic and there is no evidence of hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuroacanthocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different inherited movement disorders are associated with the finding of acanthocytosis in the peripheral blood (neuroacanthocytosis, Levine-Critchley syndrome). These include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choreo-acanthocytosis",
"     </li>",
"     <li>",
"      McLeod syndrome",
"     </li>",
"     <li>",
"      Huntington's disease-like 2",
"     </li>",
"     <li>",
"      Pantothenate-kinase associated neurodegeneration",
"     </li>",
"     <li>",
"      Abetalipoproteinemia and hypobetalipoproteinemia",
"     </li>",
"     <li>",
"      Familial acanthocytosis with paroxysmal exertion-induced dyskinesias and epilepsy (FAPED)",
"     </li>",
"     <li>",
"      Mitochondrial disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basis for acanthocytosis in these disorders is not clear, but their presence may assist in making the diagnosis. Examination of a wet blood preparation after isotonic dilution with saline increases the sensitivity and specificity of this easily performed hematologic test in the identification of neuroacanthocytic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chorea-acanthocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chorea-acanthocytosis syndrome (CHAC, choreoacanthocytosis) is a rare autosomal recessive disorder characterized by progressive neurologic disease, always including chorea, beginning in late childhood, adolescence, or adult life in association with acanthocytosis and a normal lipid profile [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The locus is on chromosome 9q21, affecting the CHAC gene encoding a sorting-associated protein named chorein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]; the gene has now been renamed VPS13A.",
"   </p>",
"   <p>",
"    The relationship between the red cell changes and neurologic manifestations is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/33\">",
"     33",
"    </a>",
"    ]. Increased degradation and phosphorylation of red cell membrane proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] and an increase in the proportion of red cell sphingomyelin, a stable, immobile component of the red cell membrane have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/35\">",
"     35",
"    </a>",
"    ] and may contribute to the acanthocytosis.",
"   </p>",
"   <p>",
"    The link between acanthocytosis and the neurologic disturbance may be due to alterations in band 3, the anion transporter found in all cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one family with symptoms compatible with CHAC but without acanthocytosis, abnormal red cell band 3 structure was found along with antibodies to neural tissue, which appeared to have specificity for band 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one family without neurologic changes, a mutation in the membrane domain of band 3 (band 3 HT) has been found, leading to acanthocytosis and increased anion transport [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of conditions that are likely to be variants of this disorder have been described. These include syndromes with chorea-acanthocytosis and myopathy and chorea-acanthocytosis with spherocytosis and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In addition, neuroacanthocytosis can occur in the McLeod syndrome (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/41\">",
"     41",
"    </a>",
"    ]. Other rare neurologic disorders have been reported to have acanthocytes. The cause of these disorders is unknown.",
"   </p>",
"   <p>",
"    In a group of four Italian patients with neuroacanthocytosis, a partial deficiency of erythrocyte protein 4.1R was identified, but the relationship, if any, of this abnormality to the neurologic disorder or to the acanthocytosis exhibited by all four patients remains undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     McLeod syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;McLeod syndrome is an X-linked anomaly of the Kell blood group system; as a result, the red cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytes react poorly with Kell antisera but behave normally in other blood group reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/43\">",
"     43",
"    </a>",
"    ]. The McLeod gene encodes a protein that has the structural characteristics of a membrane transport protein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/44\">",
"     44",
"    </a>",
"    ], but whose function is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/45\">",
"     45",
"    </a>",
"    ]. Affected cells lack the product of this gene, called KX or XK, which appears to be required for proper synthesis of the Kell antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H40#H40\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'McLeod phenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Males have variable acanthocytosis (8 to 85 percent) and mild compensated hemolysis. As noted above, focal changes in the membrane skeleton appeared to predispose to the acanthocyte phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/2\">",
"     2",
"    </a>",
"    ]; this defect may involve lack of lipid in the inner leaflet bilayer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/48\">",
"     48",
"    </a>",
"    ]. Females have only occasional acanthocytes and very mild hemolysis; the lesser severity is thought to be due to X chromosome inactivation via the Lyon effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]. Some McLeod patients develop a neuropathy, myopathy, or psychiatric symptoms, producing a syndrome that may mimic chorea-acanthocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/41,50\">",
"     41,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other disorders are associated with acanthocytes or echinocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anorexia nervosa may have acanthocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The mechanisms responsible have not been defined but changes in plasma lipids or red cell membrane proteins may be involved. The anemia seen in patients with anorexia nervosa is more often hypoplastic and not hemolytic or related to the changes in red cell morphology. The acanthocytosis is reversible with resolution of the anorexia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vitamin E deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocytes and occasional acanthocytes are a feature of vitamin E deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/53\">",
"     53",
"    </a>",
"    ]. Previously noted in premature infants due to inadequate dietary vitamin E content, this condition is now limited to patients who have fat malabsorption, often related to liver disease or cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anderson's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anderson's disease (primary hypocholesterolemia and absent apo B lipoproteins) has been associated with mild degrees of acanthocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Blood group abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthocytes have been associated with two abnormalities of the blood group systems: McLeod syndrome (see",
"    <a class=\"local\" href=\"#H9\">",
"     'McLeod syndrome'",
"    </a>",
"    above) and In(Lu) erythrocytes.",
"   </p>",
"   <p>",
"    The most common cause of the null Lutheran phenotype Lu(a-b-) is the presence of an inhibitor called In(Lu) which partially suppresses expression of Lu(a) and Lu(b) so that these antigens are undetectable by standard agglutination tests [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. The In(Lu) gene also inhibits the expression of other cell surface proteins such as CD44 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 1 person in 5000 inherits this dominantly acting inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/57\">",
"     57",
"    </a>",
"    ]. Affected patients have abnormally shaped red cells but no hemolysis. Red cell morphology may be normal, poikilocytic, or acanthocytic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/57,60\">",
"     57,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with hypothyroidism have a small number of acanthocytes (0.5 percent to 2 percent) on peripheral blood smears; however, occasional patients have more prominent acanthocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Thus, thyroid function testing may be indicated when acanthocytes are seen in the absence of any other apparent cause [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocytes are found in the blood smear of patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/5,64,65\">",
"     5,64,65",
"    </a>",
"    ]. Echinocytosis in this setting is due to a circulating factor as evidenced by the observations that incubation of normal red cells in plasma from patients with renal failure induces a similar morphologic change, while incubation of echinocytic uremic red cells in normal plasma leads to a normal discocytic shape [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/5\">",
"     5",
"    </a>",
"    ]. Echinocytosis appears to be transiently exacerbated during the first 30 minutes of hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthocytosis has been associated with some forms of hereditary spherocytosis and myelodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"    </a>",
"    .) Although dysplastic hematopoiesis with erythrocyte macrocytosis is the hallmark of myelodysplasia, some patients have 5 to 10 percent acanthocytes and acanthocytosis may be the primary reason for referral [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/67\">",
"     67",
"    </a>",
"    ]. Echinocytes are also occasionally seen in patients with pyruvate kinase deficiency, particularly after splenectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=see_link\">",
"     \"Pyruvate kinase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Postsplenectomy state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the spleen is regularly associated with red cell changes, such as Howell-Jolly bodies (nuclear fragments), variable numbers of target cells (see below) and acanthocytes. Regrowth of the spleen, either because of splenic fragmentation at the time of trauma or the presence of accessory spleens, causes these morphologic changes to disappear. As an example, in 50 patients splenectomized because of prior trauma, 17 were found to have splenic fragments (splenosis) one to 14 years later [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/68\">",
"     68",
"    </a>",
"    ]. Acanthocytes and Howell-Jolly bodies were found in 18 and 97 percent of patients with and without ultrasonically-detected splenosis, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Woronet's trait",
"    </span>",
"    &nbsp;&mdash;&nbsp;Woronet's trait is a benign, dominantly inherited condition associated with acanthocytosis (5 to 10 percent) and echinocytosis that has been reported in a single family [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/69\">",
"     69",
"    </a>",
"    ]. Red cell life span is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient acanthocytosis and hemolytic anemia followed administration of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for medical abortion in a young Nigerian woman [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TARGET CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Definition and pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target cell has an area of central density (a hyperchromic \"bulls-eye\") surrounded by a halo of pallor (",
"    <a class=\"graphic graphic_picture graphicRef80318 \" href=\"UTD.htm?4/3/4151\">",
"     picture 5",
"    </a>",
"    ). Target cells probably circulate as bell-shaped cells called codocytes. \"Wet prep\" peripheral blood smears readily demonstrate codocytes rather than targets. Thus, the targeting seen on a routine dried peripheral blood smear is probably an artifact due to the redundant cell membrane.",
"   </p>",
"   <p>",
"    Target cells are characterized by an increased surface area-to-volume ratio and it is the redundant cell membrane that accounts for the target appearance. The increase in surface area-to-volume ratio can be due to one of two causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased cell volume, as in certain hemoglobinopathies and iron deficiency",
"     </li>",
"     <li>",
"      Increased cell membrane, as in obstructive liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Target cells generally do not have a shortened survival except for those disorders with a decrease in red cell volume, such as thalassemia and iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hemoglobinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Target cells due to a reduction in cell volume can be produced by the following mechanisms: decreased hemoglobin synthesis (thalassemia or iron deficiency), the presence of certain structural mutations of hemoglobin (Hb S, C, D, and E), or primary disorders of cell hydration such as xerocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in cell membrane in target cells in obstructive liver disease results from increases in the cholesterol and phospholipid content of the membrane bilayer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The cholesterol increase is usually proportionately greater, producing an elevation in the cholesterol-to-phospholipid ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/7\">",
"     7",
"    </a>",
"    ]. These patients also have elevations in the plasma unesterified cholesterol concentration because of inhibition of lecithin-cholesterol acyl transferase (LCAT) by bile salts; the normal function of LCAT is to esterify cholesterol to cholesterol esters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The central role of abnormal plasma lipids in the formation of target cells has been demonstrated by two in vitro observations: incubation of normal red cells in plasma from patients with obstructive liver disease causes target cells in vitro; and incubation of target cells in normal plasma results in loss of the target appearance. A clinical correlate is the finding in patients with hereditary spherocytosis that the development of obstructive jaundice due to gallstones improves the hemolytic process and normalizes osmotic fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/75\">",
"     75",
"    </a>",
"    ]. In this setting, the increase in membrane surface area due to the abnormal plasma lipid profile normalizes the previously reduced surface area-to-volume ratio due to loss of membrane surface area in the spherocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Membrane instability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hereditary LCAT deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Target cells are also seen in hereditary LCAT deficiency, a rare autosomal recessive disease due to a mutation in the LCAT gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. As in acquired LCAT deficiency (see above), plasma unesterified cholesterol and phospholipid concentrations are increased. Clinical manifestations include a normocytic anemia accompanied by prominent target cell formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/78-80\">",
"     78-80",
"    </a>",
"    ], reduced red cell osmotic fragility, corneal opacities (called fish eye syndrome), low plasma HDL-cholesterol, proteinuria, and chronic renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/76,77,80\">",
"     76,77,80",
"    </a>",
"    ], but usually not premature atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/76\">",
"     76",
"    </a>",
"    ]. Serum and red cell lipids are improved in vivo when LCAT is provided by infusions of normal plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Postsplenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen normally removes excess membrane from red cells, a process called \"splenic conditioning\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The exact mechanism is not defined, although the reduction in red cell lipid content suggests that lipases may be involved. In the first few weeks following splenectomy, target cells appear, reaching levels of 2 to 10 percent. Like most other target cells, membrane lipids are increased, osmotic fragility is reduced, and the mean surface area-to-volume ratio is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9305/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. These red cells may eventually lose their excess lipid by conditioning in nonsplenic sites, leading to the gradual disappearance of target cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of morphologic alterations in red cells can be induced by changes in the cell membrane. Three of the most common are spiculated cells (echinocytes and acanthocytes) and target cells. Discovery of these abnormal red cells in the peripheral blood will point to a limited number of diagnostic possibilities and greatly assist in the evaluation of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     What are echinocytes and acanthocytes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Echinocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinocytes (burr cells) are red cells with serrated edges over the entire surface of the cell, and often appear crenated in a blood smear (",
"    <a class=\"graphic graphic_picture graphicRef62090 \" href=\"UTD.htm?17/63/18423\">",
"     picture 3",
"    </a>",
"    ). The projections of the red cell membrane are smaller and much more uniform in shape and distribution in echinocytes than in acanthocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Acanthocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthocytes have only a few spicules of varying size that project from the red cell surface at irregular intervals (",
"    <a class=\"graphic graphic_picture graphicRef80080 \" href=\"UTD.htm?14/26/14760\">",
"     picture 4",
"    </a>",
"    ). Spur cells appear to be the extreme form of acanthocytes and are seen in patients with severe liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echinocytes are often found as artifacts on blood smears and have been demonstrated in both end-stage renal disease and in liver disease.",
"     </li>",
"     <li>",
"      Patients with liver disease often have acanthocytes, echinocytes, and target cells on the peripheral blood smear. Spur cells are the extreme form of acanthocytes. They are probably acanthocytes that have been additionally remodeled by an enlarged spleen and considerably enriched in cholesterol. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acanthocytes are also commonly found in neuroacanthocytosis and some may be seen in the post-splenectomy state. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=see_link\">",
"       \"Neuroacanthocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     What are target cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target cell has an area of central density (a hyperchromic \"bulls-eye\") surrounded by a halo of pallor (",
"    <a class=\"graphic graphic_picture graphicRef80318 \" href=\"UTD.htm?4/3/4151\">",
"     picture 5",
"    </a>",
"    ). They are characterized by an increased surface area-to-volume ratio. It is the redundant cell membrane that accounts for the target appearance. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Target cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in surface area-to-volume ratio seen in target cells can be due to one of two causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased red cell volume (eg, hemoglobinopathies and iron deficiency)",
"     </li>",
"     <li>",
"      Increased red cell membrane (eg, obstructive liver disease, hereditary lecithin:cholesterol acyltransferase (LCAT) deficiency, post-splenectomy state)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/1\">",
"      Anoop P, Parker-Williams J. Morphological diagnosis of abetalipoproteinemia and the importance of a freshly prepared peripheral smear. Eur J Haematol 2009; 83:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/2\">",
"      Terada N, Fujii Y, Ueda H, et al. Ultrastructural changes of erythrocyte membrane skeletons in chorea-acanthocytosis and McLeod syndrome revealed by the quick-freezing and deep-etching method. Acta Haematol 1999; 101:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/3\">",
"      Altomare I, Desman G, Aledort LM. Echinocytosis--an unusual manifestation of hemangioma. Am J Hematol 2006; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/4\">",
"      Wong P. A basis of the acanthocytosis in inherited and acquired disorders. Med Hypotheses 2004; 62:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/5\">",
"      Hasler CR, Owen GR, Brunner W, Reinhart WH. Echinocytosis induced by haemodialysis. Nephrol Dial Transplant 1998; 13:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/6\">",
"      Owen JS, Brown DJ, Harry DS, et al. Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins. J Clin Invest 1985; 76:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/7\">",
"      Cooper RA. Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 1980; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/8\">",
"      SMITH JA, LONERGAN ET, STERLING K. SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS. N Engl J Med 1964; 271:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/9\">",
"      Grahn EP, Dietz AA, Stefani SS, Donnelly WJ. Burr cells, hemolytic anemia and cirrhosis. Am J Med 1968; 45:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/10\">",
"      Salvioli G, Rioli G, Lugli R, Salati R. Membrane lipid composition of red blood cells in liver disease: regression of spur cell anaemia after infusion of polyunsaturated phosphatidylcholine. Gut 1978; 19:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/11\">",
"      Shohet SE. Editorial: \"Acanthocytogenesis\"--or how the red cell won its spurs. N Engl J Med 1974; 290:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/12\">",
"      Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease. N Engl J Med 1974; 290:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/13\">",
"      Olivieri O, Guarini P, Negri M, et al. Increased proteolytic activity of erythrocyte membrane in spur cell anaemia. Br J Haematol 1988; 70:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/14\">",
"      Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia. Blood 1996; 87:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/15\">",
"      Vassiliadis T, Mpoumponaris A, Vakalopoulou S, et al. Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. Hepatol Res 2010; 40:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/16\">",
"      Allen DW, Manning N. Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes. Blood 1994; 84:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/17\">",
"      Chitale AA, Sterling RK, Post AB, et al. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 1998; 65:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/18\">",
"      Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/19\">",
"      Gregg RE, Wetterau JR. The molecular basis of abetalipoproteinemia. Curr Opin Lipidol 1994; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/20\">",
"      Raabe M, Flynn LM, Zlot CH, et al. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A 1998; 95:8686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/21\">",
"      Barenholz Y, Yechiel E, Cohen R, Deckelbaum RJ. Importance of cholesterol-phospholipid interaction in determining dynamics of normal and abetalipoproteinemia red blood cell membrane. Cell Biophys 1981; 3:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/22\">",
"      Iida H, Takashima Y, Maeda S, et al. Alterations in erythrocyte membrane lipids in abetalipoproteinemia: phospholipid and fatty acyl composition. Biochem Med 1984; 32:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/23\">",
"      Cooper RA, Gulbrandsen CL. The relationship between serum lipoproteins and red cell membranes in abetalipoproteinemia: deficiency of lecithin:cholesterol acyltransferase. J Lab Clin Med 1971; 78:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/24\">",
"      Lange Y, Steck TL. Mechanism of red blood cell acanthocytosis and echinocytosis in vivo. J Membr Biol 1984; 77:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/25\">",
"      Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol 2005; 18:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/26\">",
"      Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/27\">",
"      Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci 2005; 229-230:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/28\">",
"      Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients. J Neurol 2005; 252:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/29\">",
"      Hardie RJ. Acanthocytosis and neurological impairment--a review. Q J Med 1989; 71:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/30\">",
"      Lossos A, Dobson-Stone C, Monaco AP, et al. Early clinical heterogeneity in choreoacanthocytosis. Arch Neurol 2005; 62:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/31\">",
"      Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004; 56:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/32\">",
"      Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002; 10:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/33\">",
"      Asano K, Osawa Y, Yanagisawa N, et al. Erythrocyte membrane abnormalities in patients with amyotrophic chorea with acanthocythosis. Part 2. Abnormal degradation of membrane proteins. J Neurol Sci 1985; 68:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/34\">",
"      Olivieri O, De Franceschi L, Bordin L, et al. Increased membrane protein phosphorylation and anion transport activity in chorea-acanthocytosis. Haematologica 1997; 82:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/35\">",
"      Clark MR, Aminoff MJ, Chiu DT, et al. Red cell deformability and lipid composition in two forms of acanthocytosis: enrichment of acanthocytic populations by density gradient centrifugation. J Lab Clin Med 1989; 113:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/36\">",
"      Bosman GJ, Bartholomeus IG, De Grip WJ, Horstink MW. Erythrocyte anion transporter and antibrain immunoreactivity in chorea-acanthocytosis. A contribution to etiology, genetics, and diagnosis. Brain Res Bull 1994; 33:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/37\">",
"      Bruce LJ, Kay MM, Lawrence C, Tanner MJ. Band 3 HT, a human red-cell variant associated with acanthocytosis and increased anion transport, carries the mutation Pro-868--&gt;Leu in the membrane domain of band 3. Biochem J 1993; 293 ( Pt 2):317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/38\">",
"      Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol 1968; 18:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/39\">",
"      Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991; 114 ( Pt 1A):13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/40\">",
"      Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology 1985; 35:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/41\">",
"      Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol 1992; 239:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/42\">",
"      Orlacchio A, Calabresi P, Rum A, et al. Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurol 2007; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     Redman CM, Marsh WL. The Kell antigens and McLeod red cells. In: Protein Blood Group Antigens of the Human Red Cell: Structure, Function and Clinical Significance, Agre PC, Cartron JP (Eds), Johns Hopkins University Press, Baltimore 1992. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/44\">",
"      Ho M, Chelly J, Carter N, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994; 77:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/45\">",
"      Russo DC, Lee S, Reid ME, Redman CM. Point mutations causing the McLeod phenotype. Transfusion 2002; 42:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/46\">",
"      Wimer BM, Marsh WL, Taswell HF, Galey WR. Haematological changes associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1977; 36:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/47\">",
"      Taswell HF, Lewis JC, Marsh WL, et al. Erythrocyte morphology in genetic defects of the Rh and Kell blood group systems. Mayo Clin Proc 1977; 52:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/48\">",
"      Redman CM, Huima T, Robbins E, et al. Effect of phosphatidylserine on the shape of McLeod red cell acanthocytes. Blood 1989; 74:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/49\">",
"      Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1979; 42:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/50\">",
"      Takashima H, Sakai T, Iwashita H, et al. A family of McLeod syndrome, masquerading as chorea-acanthocytosis. J Neurol Sci 1994; 124:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/51\">",
"      Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J 1983; 76:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/52\">",
"      Mant MJ, Faragher BS. The haematology of anorexia nervosa. Br J Haematol 1972; 23:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/53\">",
"      Cynamon HA, Isenberg JN, Gustavson LP, Gourley WK. Erythrocyte lipid alterations in pediatric cholestatic liver disease: spur cell anemia of infancy. J Pediatr Gastroenterol Nutr 1985; 4:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/54\">",
"      Sokol RJ, Guggenheim MA, Iannaccone ST, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/55\">",
"      Muller DP, Lloyd JK, Bird AC. Long-term management of abetalipoproteinaemia. Possible role for vitamin E. Arch Dis Child 1977; 52:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/56\">",
"      Lesesve JF, Perrin J, Georges A, Morali A. Acanthocytosis in Anderson's disease. Br J Haematol 2009; 145:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/57\">",
"      Udden MM, Umeda M, Hirano Y, Marcus DM. New abnormalities in the morphology, cell surface receptors, and electrolyte metabolism of In(Lu) erythrocytes. Blood 1987; 69:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/58\">",
"      Telen MJ, Eisenbarth GS, Haynes BF. Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J Clin Invest 1983; 71:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/59\">",
"      Telen MJ. Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. Transfus Clin Biol 1995; 2:291.",
"     </a>",
"    </li>",
"    <li>",
"     Telen MJ. The Lutheran antigens and proteins affected by Lutheran regulatory genes. In: Protein Blood Group Antigens of the Human Red Cell: Structure, Function and Clinical Significance, Agre PC, Cartron JP (Eds), Johns Hopkins University Press, Baltimore 1992. p.70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/61\">",
"      Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med 1976; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/62\">",
"      Wardrop C, Hutchison HE. Red-cell shape in hypothyroidism. Lancet 1969; 1:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/63\">",
"      Perillie PE, Tembrevilla C. Letter: Red-cell changes in hypothyroidism. Lancet 1975; 2:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/64\">",
"      AHERNE WA. The burr red cell and azotaemia. J Clin Pathol 1957; 10:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/65\">",
"      LOGE JP, LANGE RD, MOORE CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958; 24:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/66\">",
"      Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/67\">",
"      Doll DC, List AF, Dayhoff DA, et al. Acanthocytosis associated with myelodysplasia. J Clin Oncol 1989; 7:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/68\">",
"      M&uuml;ller U, R&ouml;thlin M. [Splenic neoformation following trauma-induced splenectomy--diagnosis and function]. Swiss Surg 1995; :230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/69\">",
"      Beutler E, West C, Tavassoli M, Grahn E. The Woronets trait: a new familial erythrocyte anomaly. Blood Cells 1980; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/70\">",
"      Filippini A, Villa G, Corrocher R, De Franceschi L. Acute hemolytic anemia with acanthocytosis associated with high-dose misoprostol for medical abortion. Ann Emerg Med 2007; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     Gallagher PG, Forget BG, Lux SE. Disorders of the erythrocyte membrane. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), Saunders, Philadelphia 1997. p.544.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/72\">",
"      Cooper RA, Jandl JH. Bile salts and cholesterol in the pathogenesis of target cells in obstructive jaundice. J Clin Invest 1968; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/73\">",
"      Cooper RA, Diloy Puray M, Lando P, Greenverg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest 1972; 51:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/74\">",
"      Neerhout RC. Abnormalities of erythrocyte stromal lipids in hepatic disease. J Lab Clin Med 1968; 71:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/75\">",
"      Cooper RA, Jandl JH. The role of membrane lipids in the survival of red cells in hereditary spherocytosis. J Clin Invest 1969; 48:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/76\">",
"      Funke H, von Eckardstein A, Pritchard PH, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991; 88:4855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/77\">",
"      Funke H, von Eckardstein A, Pritchard PH, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest 1993; 91:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/78\">",
"      Gjone E, Torsvik H, Norum KR. Familial plasma cholesterol ester deficiency. A study of the erythrocytes. Scand J Clin Lab Invest 1968; 21:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/79\">",
"      Norum KR, Gjone E. The influence of plasma from patients with familial plasma lecithin: cholesterol acyltransferase deficiency on the lipid pattern of erythrocytes. Scand J Clin Lab Invest 1968; 22:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/80\">",
"      Frohlich J, Godolphin WJ, Reeve CE, Evelyn KA. Familial LCAT deficiency. Report of two patients from a Canadian family of Italian and Swedish descent. Scand J Clin Lab Invest Suppl 1978; 150:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/81\">",
"      de Haan LD, Werre JM, Ruben AM, et al. Alterations in size, shape and osmotic behaviour of red cells after splenectomy: a study of their age dependence. Br J Haematol 1988; 69:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/82\">",
"      Singer K, Weisz L. The life cycle of the erythrocyte after splenectomy and the problems of splenic hemolysis and target cell formation. Am J Med Sci 1945; 210:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9305/abstract/83\">",
"      Singer K, Miller EB, et al. Hematologic changes following splenectomy in man, with particular reference to target cells, hemolytic index, and lysolecithin. Am J Med Sci 1941; 202:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7088 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-A2ED1F3088-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9305=[""].join("\n");
var outline_f9_5_9305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHINOCYTES AND ACANTHOCYTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abetalipoproteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuroacanthocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chorea-acanthocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - McLeod syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vitamin E deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anderson's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Blood group abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Postsplenectomy state",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Woronet's trait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TARGET CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Definition and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hereditary LCAT deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Postsplenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      What are echinocytes and acanthocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Echinocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Acanthocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      What are target cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7088|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/51/9015\" title=\"picture 1\">",
"      Stomatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/30/3559\" title=\"picture 2\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18423\" title=\"picture 3\">",
"      Echinocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/26/14760\" title=\"picture 4\">",
"      Acanthocytes or spur cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4151\" title=\"picture 5\">",
"      Target cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=related_link\">",
"      Neuroacanthocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9306="Methotrexate-induced lung injury";
var content_f9_5_9306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methotrexate-induced lung injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Robert A Balk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9306/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/5/9306/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/5/9306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is an analogue of the vitamin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    ; it inhibits cellular proliferation by inducing an acute intracellular deficiency of certain folate coenzymes (",
"    <a class=\"graphic graphic_figure graphicRef52756 \" href=\"UTD.htm?9/39/9847\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This impairs the intracellular trafficking of single carbon groups and results in impaired synthesis of thymidine, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In addition to its antiproliferative effects, methotrexate has antiinflammatory and immunomodulating properties [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/2,3,5-7\">",
"     2,3,5-7",
"    </a>",
"    ]. It is used to treat a variety of malignancies, connective tissue diseases, and also psoriasis. Serious toxicity from methotrexate may affect the lungs, liver, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,2,8-11\">",
"     1,2,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will review the pulmonary injury that may result from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    use. Other side effects of methotrexate therapy and an approach to pulmonary toxicity associated with antineoplastic agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H10#H10\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Overview of adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung toxicity most often occurs after weeks to months of low-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, but can occur following relatively short term use of intravenous or intrathecal high-dose administration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. In a literature review of 123 cases of methotrexate pneumonitis, about one-half arose in patients receiving therapy for rheumatoid arthritis (range 2.5 to 15 mg weekly), about 20 percent arose during",
"    <span class=\"nowrap\">",
"     intensification/consolidation",
"    </span>",
"    treatment for leukemia (doses approximately 20 to 80 mg weekly), and 8 percent were in patients treated for other malignancies (weekly doses ranging from 15 to 1400 mg) (",
"    <a class=\"graphic graphic_table graphicRef55765 \" href=\"UTD.htm?7/43/7869\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise frequency with which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pulmonary toxicity occurs is difficult to assess as some reports have included patients who were receiving other cytotoxic medications, had ongoing infectious diseases, or had underlying disease processes capable of involving the lungs and pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, impure preparations of methotrexate may have played a role in some of the earlier reports of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1\">",
"     1",
"    </a>",
"    ]. Most series estimate that acute pulmonary toxicity develops in 1 to 8 percent of patients receiving methotrexate for rheumatologic condition, including rheumatoid arthritis, but some reports suggest an incidence as high as 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/11,14-25\">",
"     11,14-25",
"    </a>",
"    ]. Whether all of these cases are attributable to methotrexate is unclear. In a systematic literature review of 3463 patients with rheumatoid arthritis who were receiving methotrexate, there were 84 reported cases of pneumonitis, only 15 of which were felt to be directly attributable to methotrexate (incidence 0.43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be classified as inflammatory, infectious, and lymphoproliferative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inflammatory and fibrotic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity pneumonitis is the most common type of pulmonary toxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and is characterized by a lymphocytic infiltration of the interstitium with epithelial cell hyperplasia, small, poorly formed granulomas, and sometimes eosinophilic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1-3,9,19\">",
"     1-3,9,19",
"    </a>",
"    ]. This pattern is similar to the hypersensitivity pneumonitis associated with inhaled organic antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'Etiologic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'Lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other types of lung injury have been associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    use, including [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1-3,16\">",
"     1-3,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Organizing pneumonia (formerly called bronchiolitis obliterans with organizing pneumonia or BOOP)",
"     </li>",
"     <li>",
"      Acute interstitial pneumonia with noncardiogenic pulmonary edema",
"     </li>",
"     <li>",
"      Pulmonary fibrosis (which may be rapidly progressive) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/9,28\">",
"       9,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pleural effusion and symptomatic pleuritis occur infrequently [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In advanced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis, the lungs show extensive fibrosis and honeycombing, especially at the bases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 10 percent of patients will demonstrate fibrosis on lung biopsy.",
"   </p>",
"   <p>",
"    The precise mechanisms by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    cause pulmonary injury are unknown. Most researchers suggest that methotrexate pneumonitis is a form of hypersensitivity lung disease because there is typically fever, eosinophilia, an increase in CD4+ T cells in bronchoalveolar lavage fluid, and a mononuclear cell infiltration of the lungs with granulomatous inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Others suggest that injury may result from a direct toxic effect of methotrexate on lung tissue, while a third theory proposes that impaired host resistance to acquired or latent viral infection (eg, cytomegalovirus or Epstein-Barr virus) underlies the observed pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Support for direct toxicity comes from a mouse model that demonstrated alveolar epithelial injury, apoptosis, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/33\">",
"     33",
"    </a>",
"    ]. Finally, activation of mitogen-activated protein (MAP) kinase pathways and altered cytokine expression may contribute to the pulmonary inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary toxicity has occurred following both low and high doses and by a variety of routes of administration, suggesting that some of the pulmonary adverse effects may result from idiosyncratic mechanisms unrelated to folate antagonism. None of the proposed mechanisms account for the observation that pulmonary toxicity may remit despite continued therapy, and may not occur upon rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In summary, the mechanisms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pulmonary toxicity are unresolved and may be multiple.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    can compromise the immune response and increase the risk for opportunistic infections due to Pneumocystis carinii (renamed Pneumocystis jirovecii), cytomegalovirus, varicella-zoster virus, Nocardia, mycobacteria, or other fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Pneumocystis has been the most commonly reported agent, and has accounted for up to 40 percent of the infectious complications in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/19,35,36\">",
"     19,35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoproliferative disease (including non-Hodgkin [B cell] and other lymphomas) may appear during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy and regress after methotrexate discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/35,37-41\">",
"     35,37-41",
"    </a>",
"    ]. Among 48 patients with rheumatoid arthritis receiving methotrexate who developed a lymphoproliferative disease, the primary site was the lung in four [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/39\">",
"     39",
"    </a>",
"    ]. In a separate report, 6 of 28 cases of lymphoproliferative disease involved the lung or pleura, but details were not provided [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reversibility of this disease without specific anti-lymphoma treatment suggests that diminished immune surveillance due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may facilitate the development and expansion of malignant lymphoid clones. However, whether methotrexate-immunosuppression has a direct effect on the malignant cells or an indirect effect via recrudescence of Epstein-Barr virus (EBV) infection is not known. A portion of these cases (28 percent) are associated with EBV infection, a finding that is also seen in patients who are immunosuppressed in the setting of organ transplantation or AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H14365930#H14365930\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9750?source=see_link\">",
"     \"Pulmonary manifestations of HIV-associated lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causal relationship between lymphoma and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    use has been difficult to prove due to the increased rate of lymphoma among patients with rheumatoid arthritis. Large database studies suggest that it is unlikely that long-term oral methotrexate therapy increases the risk of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/26,42-44\">",
"     26,42-44",
"    </a>",
"    ]. As an example, in a prospective study of 19,562 patients (89,710 person-years of follow-up), with rheumatoid arthritis, similar risks of lymphoma were observed among the 68 percent of patients who received methotrexate versus those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/44\">",
"     44",
"    </a>",
"    ]. However, there was no adjustment for the severity of the arthritis, a known factor in the risk of lymphoma in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, the relationship between methotrexate use and lymphoma in patients with conditions such as rheumatoid arthritis remains uncertain. However, there are also well-documented cases of regression of lymphoma when methotrexate is held. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have identified risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pulmonary toxicity. One multicenter case-control study involving 36 patients with methotrexate-induced lung injury following treatment for rheumatoid arthritis and 82 matched controls identified the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 60 years",
"     </li>",
"     <li>",
"      Rheumatoid pleuropulmonary involvement",
"     </li>",
"     <li>",
"      Previous use of disease-modifying antirheumatic drugs",
"     </li>",
"     <li>",
"      Hypoalbuminemia (either before or during therapy)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which some of these factors may confer excess risk is unclear, although there is evidence that hyperinsulinemia, which may occur with treatment for diabetes mellitus, is associated with increased polyglutamation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/46\">",
"     46",
"    </a>",
"    ]. The previous use of disease-modifying antirheumatic drugs may be a marker for more severe rheumatoid arthritis, and hypoalbuminemia could potentially result in a lower degree of protein binding and higher free levels of methotrexate.",
"   </p>",
"   <p>",
"    Additional risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis have been suggested by others, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher weekly doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Daily, rather than weekly drug administration [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preexisting lung disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/31,48\">",
"       31,48",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H8857883\">",
"       'Prevention'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Abnormal pulmonary function tests prior to therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased elimination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (eg, as seen in renal insufficiency or with the presence of third-space fluid collections such as ascites) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/9,49\">",
"       9,49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inherited polymorphisms in some gene alleles related to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      transport and metabolism may be associated with increased risk of toxicity, but further studies are needed to validate these associations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    pulmonary toxicity may present in an acute, subacute, or chronic form. Subacute presentations are most common. The majority of patients who develop methotrexate pulmonary toxicity during chronic oral low-dose therapy do so within the first year of treatment (mean nine months) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14\">",
"     14",
"    </a>",
"    ], although cases have been reported as early as 12 days and as late as 18 years after the drug was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14,19-22,30,31,51\">",
"     14,19-22,30,31,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of acute",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis is generally nonspecific, with symptoms (fever, chills, malaise, nonproductive cough, dyspnea, chest pain) that are progressive over several days [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10,14,20-22,30,31\">",
"       10,14,20-22,30,31",
"      </a>",
"      ]. Rapid progression to respiratory failure may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,3\">",
"       1,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subacute pneumonitis manifests with the insidious onset of dyspnea (82 percent), nonproductive cough (81 percent), fever (76 percent), crackles (50 percent), and cyanosis over a few weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10,30,52\">",
"       10,30,52",
"      </a>",
"      ]. Approximately 17 percent of patients also have cutaneous manifestations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/30\">",
"       30",
"      </a>",
"      ]. Progression to pulmonary fibrosis is observed in approximately 10 percent of patients.",
"     </li>",
"     <li>",
"      Rarely,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is associated with a more chronic presentation of dyspnea, cough, and coarse crackles that progress to respiratory failure over weeks to months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10,28,53\">",
"       10,28,53",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of pulmonary involvement in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -associated lymphoproliferative disorder are poorly described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In a series of 48 patients with rheumatoid arthritis receiving methotrexate who developed a lymphoproliferative disease, four had a primary site in the lung but the exact pattern of lung involvement was not delineated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extrapulmonary toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are listed in the table and are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef80229 \" href=\"UTD.htm?4/61/5084\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical symptoms and signs of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced lung injury (eg, dyspnea, cough, diffuse radiographic opacities and fever) are nonspecific and may be caused by intercurrent infection (eg, Pneumocystis, Cryptococcus, cytomegalovirus, Herpes zoster, Nocardia, Mycobacteria), the underlying disease (eg, rheumatoid arthritis), malignancy (eg, lymphangitic tumor, lymphoproliferative disease), or a concomitant medication. Bacterial, fungal, and viral infections are more likely to have an acute presentation of fever, dyspnea, and cough with or without sputum production, while mycobacterial disease is usually more insidious in onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Initial evaluation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Pulmonary infections'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Pulmonary lymphoproliferative disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As both usual and opportunistic lung infections have been described in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , it is imperative to exclude the possibility of pulmonary infection early in the course of diagnosis and prior to initiating treatment with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pulmonary infections'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Etiology of pulmonary infiltrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While no test is absolutely diagnostic of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pneumonitis, some tests can help in the inclusion or exclusion of other processes. Radiographic evaluation, a trial of drug cessation, bronchoalveolar lavage, and lung biopsy are the primary ways to narrow the differential diagnosis when methotrexate-induced lung disease is suspected. However, bronchoscopy and lung biopsy are not necessary in most patients. A beneficial response to methotrexate withdrawal in the appropriate clinical setting may be sufficient in the patient who is not acutely or severely ill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216665\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing (eg, complete cell counts, coagulation tests, B-type natriuretic peptide [BNP], blood cultures, sputum cultures, viral serology) is performed in most patients to determine whether other disease processes are contributing to the patient's respiratory compromise.",
"   </p>",
"   <p>",
"    Up to 50 percent of patients with subacute onset of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    lung toxicity demonstrate peripheral blood eosinophilia, which strongly supports the diagnosis, when present [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse lung parenchymal opacities are usually the earliest radiographic finding in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    lung toxicity, and they may progress rapidly to patchy acinar consolidation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/17,30,54\">",
"     17,30,54",
"    </a>",
"    ]. Nodular or ill-defined acinar opacities may be diffusely scattered throughout the lung fields. Less typical chest radiographic abnormalities include hilar lymphadenopathy, atelectasis, and pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/4,53,54\">",
"     4,53,54",
"    </a>",
"    ]. The chest film is rarely normal when the disease is fully established, but may be normal in the early stages of dry cough. Patients who develop a nonproductive cough on methotrexate, but do not have changes on radiographic studies, often improve with methotrexate discontinuation, supporting the view that methotrexate lung toxicity can be radiographically silent.",
"   </p>",
"   <p>",
"    In general, high resolution computed tomographic (HRCT) scanning is superior to conventional chest radiographs for characterizing the pattern, extent, and location of lung involvement and is performed in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of HRCT patterns have been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced toxicity, all of which can be seen with infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patchy areas of ground glass attenuation with small area of consolidation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/55,57\">",
"       55,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diffuse ground glass opacities with or without reticulation or consolidation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ill-defined centrilobular nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bilateral, symmetric, lower lung zone, irregular, reticular opacities, traction bronchiectasis and architectural distortion with or without consolidation or honeycombing [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/28,57\">",
"       28,57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of HRCT abnormality correlates quantitatively with lung volume reductions on pulmonary function testing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/55,59\">",
"     55,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiographic manifestations of pulmonary lymphoproliferative disease associated with rheumatoid arthritis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are poorly described; pleural effusion has been reported in a few cases in addition to single or multiple nodular opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14,35,37-40\">",
"     14,35,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests (PFTs) are helpful for characterizing the pattern (eg obstructive, restrictive) and severity of respiratory impairment in patients with respiratory symptoms. Among patients suspected of having",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -related lung injury, PFTs are primarily performed in those who present with an indolent onset of dyspnea or cough during methotrexate therapy, rather than a more fulminant presentation or respiratory compromise.",
"   </p>",
"   <p>",
"    PFTs in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis typically reveal a restrictive pattern with a decrease in the diffusing capacity for carbon monoxide (DLCO), hypoxemia, and an increased alveolar-arterial (A-a) gradient (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Some reports have noted worsening of airflow obstruction or development of a restrictive pattern with long-term, low-dose methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/60-62\">",
"     60-62",
"    </a>",
"    ], but other reports have not found a clinically significant decrease in pulmonary function in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/51,60,63\">",
"     51,60,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of screening pulmonary function tests for the prevention or early detection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis is not well established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As interstitial lung disease is a risk factor for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis, some experts recommend baseline pulmonary function testing prior to initiating chronic methotrexate to identify underlying interstitial lung disease and to use as a baseline in case of a later onset of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/64\">",
"       64",
"      </a>",
"      ]. We typically perform baseline pulmonary function tests prior to initiation of methotrexate, if the patient reports dyspnea on exertion or if the pretreatment chest radiograph is abnormal. We avoid use of methotrexate in patients with more than mild respiratory impairment at baseline (eg, DLCO &lt;70 percent predicted) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The value of routine screening for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      lung toxicity was assessed in a prospective study of 124 patients with rheumatologic diseases receiving long-term oral methotrexate. Surveillance spirometry, lung volumes, and DLCO were",
"      <strong>",
"       not",
"      </strong>",
"      helpful in the preclinical diagnosis of methotrexate pneumonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage (BAL) is performed in patients with new onset lung disease complicating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, when it is necessary to exclude processes such as infection or malignancy (eg, in the presence of fever, widespread or nodular opacities on chest imaging, or rapidly progressive respiratory impairment). BAL is more helpful in ruling out processes such as infection and lymphangitic tumor spread, than in making a definitive diagnosis of methotrexate pneumonitis.",
"   </p>",
"   <p>",
"    BAL samples are sent for bacterial, fungal, and mycobacterial smear, special stains, and culture. Samples are also sent for cytologic examination for viral inclusion bodies and malignant cells. Samples are sent for viral culture and immunohistochemistry, where available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Bronchoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the BAL fluid of patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis, cell counts reveal lymphocytic predominance (eg, 33 to 68 percent) with an increase in the number of CD4 lymphocytes and the",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. These findings are not specific and can be seen in a variety of inflammatory lung processes, including sarcoidosis, berylliosis, rheumatoid arthritis, and miliary tuberculosis; other forms of hypersensitivity pneumonitis may yield similar results, although the",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio is usually decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atypical epithelial cells are sometimes seen in BAL fluid from patients with pulmonary fibrosis due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,3,9\">",
"     1,3,9",
"    </a>",
"    ]. This manifestation may be detected earlier in the course of the disease than histologic evidence of fibrosis on lung biopsy.",
"   </p>",
"   <p>",
"    In patients without specific contraindications, transbronchial lung biopsy may improve the likelihood of identifying lymphangitic spread of tumor or an invasive infection over BAL alone. In addition, biopsy allows distinction between colonization and invasion in fungal (or viral) infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link&amp;anchor=H3441165#H3441165\">",
"     \"Flexible bronchoscopy: Indications and contraindications\", section on 'Contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link&amp;anchor=H1420242#H1420242\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Lung sampling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary histopathology may be helpful in establishing the diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pulmonary toxicity, but is not always required. Patients who respond quickly to drug discontinuation generally do not need a lung biopsy. In contrast, a lung biopsy is indicated when the patient has acute, progressive or severe disease and the cause of the pneumonitis is uncertain or when lymphoproliferative disease is suspected on the basis of nodular opacities. Surgical lung biopsy can be obtained by video-assisted thoracoscopic surgery or open thoracotomy, depending on the expertise and preference of the surgeon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H5#H5\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Surgical lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung biopsy can help to distinguish",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced lung disease from other processes, such as infection, neoplasia, and lung involvement by the underlying disease (eg, rheumatoid arthritis), although this is not always possible. In a patient with rheumatoid arthritis, for example, poorly formed granulomas with scattered eosinophils, consistent with hypersensitivity pneumonitis due to methotrexate, are distinct from the lung injury usually associated with rheumatoid arthritis. The latter is typically characterized by a usual interstitial pneumonia (idiopathic pulmonary fibrosis) or nonspecific interstitial pneumonia pattern (NSIP). On the other hand, acute interstitial pneumonitis (AIP) and organizing pneumonia (OP) have been described with methotrexate alone and with rheumatoid arthritis in the absence of methotrexate; thus, the finding of AIP or OP does not differentiate these processes. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Inflammatory and fibrotic lung disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link&amp;anchor=H9#H9\">",
"     \"Interstitial lung disease in rheumatoid arthritis\", section on 'Lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pulmonary toxicity is based on the combination of the appropriate clinical setting, clinical manifestations, radiographic abnormalities, bronchoalveolar lavage findings, lung histology (when available), and response to drug discontinuation.",
"   </p>",
"   <p>",
"    Given the absence of a definitive diagnostic test, a set of diagnostic criteria has been proposed to establish a diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , the",
"    <strong>",
"     major",
"    </strong>",
"    criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypersensitivity pneumonitis by histopathology without evidence of pathogenic organisms",
"     </li>",
"     <li>",
"      Radiographic evidence of diffuse pulmonary ground glass or consolidative opacities",
"     </li>",
"     <li>",
"      Blood cultures (if febrile) and initial sputum cultures (if sputum is produced) that are negative for pathogenic organisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     minor",
"    </strong>",
"    criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shortness of breath for less than eight weeks",
"     </li>",
"     <li>",
"      Nonproductive cough",
"     </li>",
"     <li>",
"      Oxygen saturation &le;90 percent on room air at the time of initial evaluation",
"     </li>",
"     <li>",
"      DLCO &le;70 percent of predicted for age",
"     </li>",
"     <li>",
"      Leukocyte count &le;15,000",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    pneumonitis is characterized as \"definite\" if major criteria 1 or 2",
"    <strong>",
"     and",
"    </strong>",
"    major criterion 3 are present in conjunction with three of the five minor criteria. \"Probable\" methotrexate pneumonitis is present if major criteria 2 and 3 plus two of the five minor criteria are present.",
"   </p>",
"   <p>",
"    While this combination of factors can support a diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced lung injury, the scoring system is predominantly useful in assuring comparable patient populations in different clinical trials. The clinical utility of the scoring system has not been adequately validated, and it should not be strictly relied upon to establish the diagnosis in a given patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced lung toxicity has not been established and no prospective trials of therapy have been performed. The treatments for opportunistic infections in the lung and lymphoproliferative disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link&amp;anchor=H26#H26\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Selection of initial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H14365930#H14365930\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216711\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is mandatory to exclude an infectious etiology of the pulmonary findings [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/12\">",
"       12",
"      </a>",
"      ]. Empiric antimicrobial therapy directed at likely pathogens may be indicated while definitive procedures and cultures are performed.",
"     </li>",
"     <li>",
"      Discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is the initial step in management. In most cases, clinical improvement occurs within days of stopping the drug, followed by radiographic improvement over several weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/4\">",
"       4",
"      </a>",
"      ]. While there are reports of successful rechallenge with methotrexate and even regression of pulmonary toxicity despite continued therapy, neither of these approaches is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,3,5,9,14,17,22\">",
"       1,3,5,9,14,17,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Supportive care includes supplemental oxygen as indicated by pulse oximetry and mechanical ventilation, if clinically indicated.",
"     </li>",
"     <li>",
"      Systemic glucocorticoids are used in selected patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216718\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and histological similarities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -induced pneumonitis to hypersensitivity pneumonitis imply a role for glucocorticoids. No prospective trials of glucocorticoid therapy have been performed, but clinical experience and case reports suggest that use of glucocorticoids accelerates the recovery of pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10,23,30,68,69\">",
"     10,23,30,68,69",
"    </a>",
"    ], although fatalities may still occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/69\">",
"     69",
"    </a>",
"    ]. The efficacy of glucocorticoid therapy is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of nine patients with otherwise unexplained symptoms who experienced a clinical course consistent with a drug-induced lung reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , three had a moderate severity of findings and fully recovered with discontinuation of methotrexate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/23\">",
"       23",
"      </a>",
"      ]. All six patients who had marked respiratory compromise recovered fully with methotrexate discontinuation and high-dose glucocorticoids.",
"     </li>",
"     <li>",
"      In a second series of 9 patients with presumed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis, methotrexate was discontinued in all, and glucocorticoids given to eight [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/10\">",
"       10",
"      </a>",
"      ]. One patient&rsquo;s illness resolved completely after 5 days, five improved steadily over the course of 3 to 20 weeks; one continued to have respiratory insufficiency requiring periodic oxygen supplementation at 19 months; and two died of respiratory failure.",
"     </li>",
"     <li>",
"      Among 6 patients who developed &ldquo;life-threatening&rdquo;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pneumonitis, drug discontinuation and administration of high-dose glucocorticoids were associated with improvement in five, but death in one [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third report, one of three patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pneumonitis died despite institution of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ; the others recovered completely [",
"      <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although systemic glucocorticoid therapy may accelerate recovery, it does not appear to prevent fatalities. We typically reserve glucocorticoids for patients with more severe initial pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than a 4 percent decrease from baseline) or worsening clinical status despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    discontinuation.",
"   </p>",
"   <p>",
"    Systemic glucocorticoid therapy is typically initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally or the equivalent (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 3",
"    </a>",
"    ). If the patient is severely ill, intravenous glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once or twice a day are administered and transitioned to oral prednisone as the patient stabilizes. Tapering of glucocorticoid therapy is dependent upon the clinical response, as assessed by improvement in the clinical, physiologic (pulmonary function tests), and radiographic parameters, but generally occurs over a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/5,17\">",
"     5,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with advanced pulmonary fibrosis (eg, extensive reticular opacities and honeycombing on HRCT or fibrosis on biopsy) and a slowly progressive course, we are cautious in administering systemic glucocorticoids due to their known side effects and unlikely benefit.",
"   </p>",
"   <p>",
"    The potential adverse effects of glucocorticoid therapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216036\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients recover from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pneumonitis, although some physiologic abnormalities may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Thus, aggressive supportive care for acute respiratory failure is reasonable while glucocorticoids are administered. A systematic review reported a mortality rate of 13 percent, although other series have reported lower rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/1,10,53\">",
"     1,10,53",
"    </a>",
"    ]. The cause of the discrepancy in reported fatality rates is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216732\">",
"    <span class=\"h2\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high rate of relapse of lung disease has been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    rechallenge, although individual patients who tolerate rechallenge have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, several cases of fatal lung toxicity have been reported with rechallenge. Thus, rechallenge is avoided, and an alternate form of therapy employed, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8857883\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many adverse reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , such as stomatitis, and myelosuppression, can be alleviated or prevented by the addition of supplemental folic or folinic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ), which selectively &ldquo;rescues&rdquo; normal cells from methotrexate toxicity without altering its therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/31,70-72\">",
"     31,70-72",
"    </a>",
"    ], the repletion of folate stores does",
"    <strong>",
"     not",
"    </strong>",
"    reduce the risk for methotrexate pulmonary toxicity, suggesting that mechanisms other than intracellular folate depletion are involved in their genesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Folic acid supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Rationale for leucovorin rescue'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Given that underlying pulmonary fibrosis may be a risk factor for developing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    lung toxicity, most experts obtain a chest radiograph prior to initiating long-term methotrexate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/5/9306/abstract/14,62,64,73\">",
"     14,62,64,73",
"    </a>",
"    ]. If the chest radiograph suggests underlying interstitial lung disease, further evaluation with pulmonary function testing and high resolution computed tomography may be indicated. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pulmonary function testing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link&amp;anchor=H5#H5\">",
"     \"Interstitial lung disease in rheumatoid arthritis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternate agent instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is preferred for patients who have evidence of underlying interstitial lung disease. The baseline radiograph can also be useful for future comparison should a patient develop dyspnea while on methotrexate.",
"   </p>",
"   <p>",
"    To reduce the risk of pulmonary toxicity, dose adjustments of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be needed in patients who have renal or hepatic dysfunction, a third space fluid collection (ie, ascites or pleural effusion), or are elderly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H21#H21\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8857585\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14792058\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnostic evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung toxicity most often develops after chronic low-dose therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , but can occur following short-term administration of high-dose methotrexate. Risk factors for methotrexate-induced lung toxicity include age greater than 60, rheumatoid pleuropulmonary involvement, previous use of disease-modifying antirheumatic drugs, hypoalbuminemia, higher weekly doses of methotrexate, pre-existing lung disease, and decreased elimination of methotrexate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      -induced pulmonary toxicity may present in acute, subacute, or chronic forms; subacute presentations are most common. The acute presentation typically includes fever, chills, malaise, nonproductive cough, dyspnea, and chest pain; the subacute presentation is characterized by a more insidious onset of dyspnea, cough, and fever. The majority of patients who develop methotrexate pulmonary toxicity do so within the first year of therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing (eg, complete cell counts and differential, coagulation tests, brain natriuretic peptide [BNP], blood cultures, sputum cultures, viral serology) is used to determine whether other disease processes are contributing to the patient's respiratory compromise. Up to 50 percent of patients with subacute",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      lung toxicity have peripheral blood eosinophilia. (See",
"      <a class=\"local\" href=\"#H216665\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      lung toxicity is characterized by a variety of radiographic patterns on high resolution computed tomography (HRCT), including patchy or diffuse ground glass attenuation, ill-defined centrilobular nodules, and bilateral, reticular opacities associated with traction bronchiectasis and architectural distortion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopy with bronchoalveolar lavage (BAL) may be indicated in the evaluation of lung disease complicating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      therapy in patients whose symptoms and pattern of onset suggest infection or malignancy (eg, acute onset, fever, widespread or nodular radiographic opacities, moderate to severe respiratory impairment). BAL is more helpful in ruling out an infectious or neoplastic etiology than in making a definitive diagnosis of methotrexate pneumonitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without specific contraindications, transbronchial lung biopsy performed at the time of bronchoscopy may improve the likelihood of identifying lymphangitic spread of tumor or an invasive infection over BAL alone. Surgical lung biopsy is indicated when the patient has progressive or severe respiratory impairment and the cause of the pneumonitis is uncertain, or if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced lymphoproliferative disease is suspected. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bronchoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Lung biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical histopathology of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis is characterized by lymphocytic infiltration of the interstitium, epithelial cell hyperplasia, and cytologic dysplasia. Small, poorly formed granulomas and eosinophilic infiltration may be present, suggestive of hypersensitivity pneumonitis. In chronic methotrexate pneumonitis, extensive fibrosis and honeycombing are seen, especially at the lung bases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lung biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pulmonary toxicity is typically based on the combination of the appropriate clinical setting, clinical manifestations, radiographic abnormalities, and either the response to drug withdrawal or the results of bronchoalveolar lavage and lung histology. A beneficial response to methotrexate withdrawal in the appropriate clinical setting may be sufficient in the patient who is not acutely or severely ill. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced lung injury includes opportunistic infection (eg, Pneumocystis, Cryptococcus, cytomegalovirus, Herpes zoster, Nocardia), the underlying disease (eg, rheumatoid arthritis), malignancy (eg, lymphangitic tumor, lymphoproliferative disease), and lung toxicity from a concomitant medication. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14792066\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      lung injury starts with discontinuation of the drug. In most cases, clinical improvement occurs within days to weeks of stopping the drug, followed by improvement in the chest radiograph over several weeks. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute or subacute presumed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -induced pulmonary toxicity and moderate&nbsp;to severe respiratory impairment (eg, a decrease in room air oxygen saturation below 90 percent or more than a 4 percent decrease from baseline), we suggest initiating systemic glucocorticoid therapy, rather than observation and supportive care alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Among the factors to consider in the decision to initiate glucocorticoid therapy are the rapidity of clinical deterioration, the worsening of respiratory status despite discontinuation of methotrexate, and the presence of serious comorbid conditions that would increase the risk of serious adverse effects from glucocorticoids (eg, infection, myelosuppression, uncontrolled diabetes mellitus).",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      The usual initial dose of glucocorticoid is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally (or the equivalent), or for impending respiratory failure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is administered once or twice a day intravenously (",
"      <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"       table 3",
"      </a>",
"      ). Tapering is guided by the clinical response. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with evidence of advanced pulmonary fibrosis (eg, extensive honeycombing on HRCT or biopsy), we avoid using systemic glucocorticoids because of the known side effects and uncertain benefit. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      rechallenge should be avoided, due to the high risk of recurrent disease. (See",
"      <a class=\"local\" href=\"#H216732\">",
"       'Rechallenge'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/1\">",
"      Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/2\">",
"      Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/3\">",
"      Lynch JP 3rd, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/4\">",
"      Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/5\">",
"      Kremer JM. Methotrexate update. Scand J Rheumatol 1996; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/6\">",
"      Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/7\">",
"      Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/8\">",
"      Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4:723.",
"     </a>",
"    </li>",
"    <li>",
"     Bedrosian CW. Iatrogenic and toxic injury. In: Pulmonary Pathology, Dail DH, Hammar SP (Eds), Springer Verlag, New York 1988. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/10\">",
"      Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/11\">",
"      Acute lymphocytic leukemia in children: maintenance therapy with methotrexat administered intermittently. Acute Leukemia Group B. JAMA 1969; 207:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/12\">",
"      Bernstein ML, Sobel DB, Wimmer RS. Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. Cancer 1982; 50:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/13\">",
"      Le Guillou F, Dominique S, Dubruille V, et al. [Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration]. Rev Mal Respir 2003; 20:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/14\">",
"      Kremer JM, Alarc&oacute;n GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/15\">",
"      McKendry RJ, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients. Arch Intern Med 1989; 149:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/16\">",
"      Rosenow EC 3rd, Myers JL, Swensen SJ, Pisani RJ. Drug-induced pulmonary disease. An update. Chest 1992; 102:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/17\">",
"      Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med 1977; 62:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/18\">",
"      Kinder AJ, Hassell AB, Brand J, et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005; 44:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/19\">",
"      Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996; 35:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/20\">",
"      Hassell A, Dawes P. Serious problems with methotrexate? Br J Rheumatol 1994; 33:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/21\">",
"      Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/22\">",
"      Rosenow EC 3rd. Drug-induced pulmonary disease. Dis Mon 1994; 40:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/23\">",
"      Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 16:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/24\">",
"      Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001; 94:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/25\">",
"      Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/26\">",
"      Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/27\">",
"      Conaghan PG, Quinn DI, Brooks PM, Day RO. Hazards of low dose methotrexate. Aust N Z J Med 1995; 25:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/28\">",
"      Bedrossian CW, Miller WC, Luna MA. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J 1979; 72:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/29\">",
"      Kim YJ, Song M, Ryu JC. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009; 256:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/30\">",
"      St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985; 145:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/31\">",
"      Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/32\">",
"      Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf 2009; 8:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/33\">",
"      Ohbayashi M, Suzuki M, Yashiro Y, et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. J Toxicol Sci 2010; 35:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/34\">",
"      Morice AH, Lai WK. Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate. Thorax 1995; 50:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/35\">",
"      Weinblatt ME. Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol 1996; 35:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/36\">",
"      LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/37\">",
"      Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/38\">",
"      Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/39\">",
"      Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007; 34:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/40\">",
"      Rizzi R, Curci P, Delia M, et al. Spontaneous remission of \"methotrexate-associated lymphoproliferative disorders\" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2009; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/41\">",
"      Homsi S, Alexandrescu DT, Milojkovic N, et al. Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate. Dermatol Online J 2010; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/42\">",
"      Bologna C, Picot MC, Jorgensen C, et al. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 1997; 56:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/43\">",
"      Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/44\">",
"      Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/45\">",
"      Alarcon, GS, Kremer, JM, Macaluso, M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study. Ann Intern Med 1997; 127:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/46\">",
"      Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/47\">",
"      Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/48\">",
"      Sany, J, Anaya, JM, Gutierrez, M, et al. Predictive value of pulmonary function tests in methotrexate induced pneumonitis in rheumatoid arthritis. Arthritis Rheum 1992; 35:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/49\">",
"      The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995; 22:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/50\">",
"      Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007; 46:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/51\">",
"      Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41:262.",
"     </a>",
"    </li>",
"    <li>",
"     Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial lung disease, 5th, Schwarz MI, King TE Jr.  (Eds), People's Medical Publishing House, Shelton, CT 201. p.637.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/53\">",
"      van der Veen MJ, Dekker JJ, Dinant HJ, et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995; 22:1766.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnosis of Diseases of the Chest, 3rd ed, Fraser RG, Pare JAP, Pare PD, et al (Eds), WB Saunders, Philadelphia 1991. p.2433.",
"    </li>",
"    <li>",
"     High-resolution CT of the Lung, 2nd ed, Webb WR, Muller NL, Naidich DP (Eds), Lippincott-Raven, Philadelphia 1996. p.125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/56\">",
"      Biederer J, Schnabel A, Muhle C, et al. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 2004; 14:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/57\">",
"      Padley SP, Adler B, Hansell DM, M&uuml;ller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/58\">",
"      Arakawa H, Yamasaki M, Kurihara Y, et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 2003; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/59\">",
"      Leonel D, Lucia C, A M, et al. Pulmonary function test: its correlation with pulmonary high-resolution computed tomography in patients with rheumatoid arthritis. Rheumatol Int 2012; 32:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/60\">",
"      Beyeler C, Jordi B, Gerber NJ, Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1996; 35:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/61\">",
"      Dayton CS, Schwartz DA, Sprince NL, et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995; 151:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/62\">",
"      Khadadah ME, Jayakrishnan B, Al-Gorair S, et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis--a prospective study. Rheumatol Int 2002; 22:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/63\">",
"      Wall MA, Wohl ME, Jaffe N, Strieder DJ. Lung function in adolescents receiving high-dose methotrexate. Pediatrics 1979; 63:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/64\">",
"      Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/65\">",
"      Cottin V, T&eacute;bib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/66\">",
"      White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989; 139:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/67\">",
"      Schnabel A, Richter C, Bauerfeind S, Gross WL. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/68\">",
"      Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis 2010; 4:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/69\">",
"      Rondon F, Mendez O, Spinel N, et al. Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review. Clin Rheumatol 2011; 30:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/70\">",
"      Dijkmans BA. Folate supplementation and methotrexate. Br J Rheumatol 1995; 34:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/71\">",
"      Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/72\">",
"      Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/5/9306/abstract/73\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4372 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9306=[""].join("\n");
var outline_f9_5_9306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8857585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inflammatory and fibrotic lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216665\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216711\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216718\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216036\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216732\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8857883\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8857585\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14792058\">",
"      Clinical manifestations and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14792066\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4372|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/39/9847\" title=\"figure 1\">",
"      Folate pathway MTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/43/7869\" title=\"table 1\">",
"      Diseases associated with methotrexate pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/61/5084\" title=\"table 2\">",
"      Adverse effects of methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 3\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=related_link\" title=\"calculator 1\">",
"      Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9750?source=related_link\">",
"      Pulmonary manifestations of HIV-associated lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_5_9307="ASA physical status scale";
var content_f9_5_9307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Society of Anesthesiologists physical status scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Class I:",
"       </td>",
"       <td>",
"        A normal healthy individual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class II:",
"       </td>",
"       <td>",
"        A patient with mild to moderate systemic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class III:",
"       </td>",
"       <td>",
"        A patient with severe systemic disease that limits activity but is not incapacitating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class IV:",
"       </td>",
"       <td>",
"        A patient with incapacitating systemic disease that is a constant threat to life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class V:",
"       </td>",
"       <td>",
"        A moribund patient who is not expected to survive 24 hours with or without operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class VI:",
"       </td>",
"       <td>",
"        A clinically dead patient being maintained for harvesting organs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ASA - E:",
"       </td>",
"       <td>",
"        Emergent operations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Feigal DW, Med Clin North Am 1979; 63:1131.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9307=[""].join("\n");
var outline_f9_5_9307=null;
var title_f9_5_9308="Selective IgM deficiency patient instructions re infections";
var content_f9_5_9308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient instructions regarding fever and infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Selective IgM deficiency - What you should know about infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Healthcare provider's name and contact information:",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        What is it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selective IgM deficiency is a condition of the immune system in which a person has very low levels of a protein called antibody M in the blood. In people with this condition, the levels of other antibodies are normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        What problems can occur in people with selective IgM deficiency?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Some people with selective IgM deficiency are completely well and have no problems.",
"        </p>",
"        <p>",
"         Others get severe infections or repeated infections with viruses and bacteria. Such infections most commonly involve the lungs, sinuses, ears, skin, or blood stream (called sepsis).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        What should I do if I get sick?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         You should contact a healthcare provider if you have a fever (a temperature higher than 100.5&deg;F or 38&deg;C) or an infection that seems to be anything worse than a normal cold.",
"        </p>",
"        <p>",
"         You should tell the provider that you have selective IgM deficiency and that you have been told to be seen when you get sick.",
"        </p>",
"        <p>",
"         Blood stream infections can begin as a fever that does not seem to be related to a cold or an infection in a specific part of the body. If you develop an unexplained fever like this, see a healthcare provider right away. Your blood may need to be tested for infection.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9308=[""].join("\n");
var outline_f9_5_9308=null;
var title_f9_5_9309="Low tidal volume vent";
var content_f9_5_9309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low tidal volume ventilation in patients with acute respiratory distress syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"9\">",
"        Initial ventilator settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        Calculate predicted body weight (PBW)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Male =",
"       </td>",
"       <td colspan=\"8\">",
"        50 + 2.3 [height (inches) - 60]",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"8\">",
"        50 + 0.91 [height (cm) - 152.4]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Female =",
"       </td>",
"       <td colspan=\"8\">",
"        45.5 + 2.3 [height (inches) - 60]",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"8\">",
"        45.5 + 0.91 [height (cm) - 152.4]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"9\">",
"        Set mode to volume assist-control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"9\">",
"        Set initial tidal volume to 8 mL/kg PBW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"9\">",
"        Reduce tidal volume to 7 and then to 6 mL/kg over 1 to 3 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        Set initial ventilator rate &le;35 breaths/min to match baseline minute ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"9\">",
"        Subsequent tidal volume adjustment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        Plateau pressure goal: Pplat &le;30 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"9\">",
"        Check inspiratory plateau pressure with 0.5 second inspiratory pause at least every four hours and after each change in PEEP or tidal volume.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"9\">",
"        If Pplat &gt;30 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O, decrease tidal volume in 1 mL/kg PBW steps to 5 or if necessary to 4 mL/kg PBW.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"9\">",
"        If Pplat &lt;25 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O and tidal volume &lt;6 mL/kg, increase tidal volume by 1 mL/kg PBW until Pplat &gt;25 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O or tidal volume = 6 mL/kg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"9\">",
"        If breath stacking (autoPEEP) or severe dyspnea occurs, tidal volume may be increased to 7 or 8 mL/kg PBW if Pplat remains &le;30 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"9\">",
"        Arterial oxygenation and PEEP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        Oxygenation goal: PaO",
"        <sub>",
"         2",
"        </sub>",
"        55 to 80 mmHg or SpO",
"        <sub>",
"         2",
"        </sub>",
"        88 to 95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        Use these FiO",
"        <sub>",
"         2",
"        </sub>",
"        /PEEP combinations to achieve oxygenation goal:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        FiO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        PEEP",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5 to 8",
"       </td>",
"       <td>",
"        8 to 10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10 to 14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14 to 18",
"       </td>",
"       <td>",
"        18 to 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"9\">",
"        PEEP should be applied starting with the minimum value for a given FiO",
"        <sub>",
"         2",
"        </sub>",
"        .",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Pplat: plateau pressure; PaO",
"    <sub>",
"     2",
"    </sub>",
"    : arterial oxygen tension; SpO",
"    <sub>",
"     2",
"    </sub>",
"    : oxyhemoglobin saturation; PEEP: positive end-expiratory pressure; FiO2: fraction of inspired oxygen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9309=[""].join("\n");
var outline_f9_5_9309=null;
var title_f9_5_9310="SEER incidence prostate 2000 to 2006";
var content_f9_5_9310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Age-specific (crude) SEER* prostate cancer&bull; incidence rates, all ages, all races, male (2000-2006)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 384px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Surveillance, Epidemiology and End Results.",
"     <br>",
"      * SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Cancer sites include invasive cases unless otherwise noted.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <a href=\"file://seer.cancer.gov/\">",
"      seer.cancer.gov",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9310=[""].join("\n");
var outline_f9_5_9310=null;
var title_f9_5_9311="Treatment algorithm for normal or slow transit constipation";
var content_f9_5_9311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F88131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F88131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for normal or slow transit constipation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 604px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEG: polyethylene glycol; MOM: milk of magnesia; GI: gastrointestinal.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_5_9311=[""].join("\n");
var outline_f9_5_9311=null;
